Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
1
BENZAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF 5HT2C RECEPTOR ASSOCIATED
DISEASES
FIELD OF THE INVENTION
The present invention relates to certain substituted-2,3,4,5-tetrahydro-3-
benzazepine
derivatives that are modulators of the 5HT2c receptor. Accordingly, compounds
of the present
invention are useful for the prophylaxis or treatment of 5HT2C receptor
associated diseases,
conditions or disorders, such as, obesity and related disorders.
BACKGROUND OF THE INVENTION
Obesity is a life-threatening disorder in which there is an increased risk of
morbidity and
mortality arising from concomitant diseases such as, but not limited to, type
II diabetes,
hypertension, stroke, certain forms of cancers and gallbladder disease.
Obesity has become a major healthcare issue in the Western World and
increasingly in
some third world countries. The increase in the number of obese people is due
largely to the
increasing preference for high fat content foods but also, and this can be a
more important factor,
the decrease in activity in most people's lives. In the last 10 years there
has been a 30% increase in
the incidence of obesity in the USA and that about 30% of the population of
the USA is now
considered obese. In spite, of the growing awareness of the health concerns
linked to obesity the
percentage of individuals that are overweight or obese continue to increase.
In fact, the percentage
of children and adolescents who are defined as overweight has more than
doubled since the early
1970s and about 13 percent of children and adolescents are now seriously
overweight. The most
significant concern, from a public health perspective, is that children who
are overweight grow up
to be overweight or obese adults, and accordingly are at greater risk for
major health problems.
Therefore, it appears that the number of individuals that are overweight or
obese will continue to
increase..
Whether someone is classified as overweight or obese is generally determined
on the basis
of his or her body mass index (BMI) which is calculated by dividing their body
weight (kilograms -
Kg) by their height squared (meters squared - m). Thus, the units for BMI are
Kg/m2. The BMI is
more highly correlated with body fat than any other indicator of height and
weight. A person is
considered overweight when they have a BMI in the range of 25-30 kg/m2.
Whereas a person with
a BMI over 30 kg/m2 is classified as obese and obesity is further divided into
three classes, Class I
(BMI of about 30 to about 34.9 kg/m), Class II (BMI of about 35 to 39.9 kg/m2)
and Class III
(about 40 kg/m2 or greater); see TABLE 1 below for complete classifications.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
2
TABLE 1
CLASSIFICATION OF WEIGHT BY BODY MASS INDEX (BMI)
BMI CLASSIFICATION
< 18.5 Underweight
18.5-24.9 Normal
25.0-29.9 Overweight
30.0-34.9 Obesity (Class I)
35.0-39.9 Obesity (Class II)
>40 Extreme Obesity (Class III)
As the BMI increases for an individual there is an increased risk of morbidity
and mortality relative
to an individual with normal BMI. Accordingly, overweight and obese
individuals (BMI of about
25 kg/mz and above) are at increased risk for physical ailments such as, but
not limited to, high
blood pressure, cardiovascular disease (particularly hypertension), high blood
cholesterol,
dyslipidemia, type II (non-insulin dependent) diabetes, insulin resistance,
glucose intolerance,
hyperinsulinemia, coronary heart disease, angina pectoris, congestive heart
failure, stroke,
gallstones, cholescystitis and cholelithiasis, gout, osteoarthritis,
obstructive sleep apnea and
respiratory problems, some types of cancer (such as endometrial, breast,
prostate, and colon),
complications of pregnancy, poor female reproductive health (such as menstrual
irregularities,
infertility, irregular ovulation), diseases of reproduction (such as sexual
dysfunction, both male and
female, including male erectile dysfunction), bladder control problems (such
as stress incontinence),
uric acid nephrolithiasis, psychological disorders (such as depression, eating
disorders, distorted
body image, and low self esteem). Research has shown that even a modest
reduction in body
weight can correspond to a significant reduction in the risk of developing
other ailments, such as,
but not limited to, coronary heart disease.
As mentioned above, obesity increases the risk of developing cardiovascular
diseases.
Coronary insufficiency, atheromatous disease, and cardiac insufficiency are at
the forefront of the
cardiovascular complications induced by obesity. The incidence of coronary
diseases is doubled in
subjects less than 50 years of age who are 30% overweight. The diabetes
patient faces a 30% reduced
lifespan. After age 45, people with diabetes are about three times more likely
than people without
diabetes to have significant heart disease and up to five times more likely to
have a stroke. These
findings emphasize the inter-relations between risks factors for NIDDM and
coronary heart disease
and the potential value of an integrated approach to the prevention of these
conditions based on the
prevention of obesity [Perry, I. J., et al. BMJ 310, 560-564 (1995)]. It is
estimated that if the entire
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
3
population had an ideal weight, the risk of coronary insufficiency would
decrease by 25% and the risk
of cardiac insufficiency and of cerebral vascular accidents by 35%.
Diabetes has also been implicated in the development of kidney disease, eye
diseases and
nervous-system problems. Kidney disease, also called nephropathy, occurs when
the kidney's "filter
mechanism" is damaged and protein leaks into urine in excessive amounts and
eventually the kidney
fails. Diabetes is also a leading cause of damage to the retina and increases
the risk of cataracts and
glaucoma. Finally, diabetes is associated with nerve damage, especially in the
legs and feet, which
interferes with the ability to sense pain and contributes to serious
infections. Taken together, diabetes
complications are one of the nation's leading causes of death.
The first line of treatment for individuals that are overweight or obese is to
offer diet and
life style advice, such as, reducing the fat content of their diet and
increasing their physical activity.
However many patients find these difficult to maintain and need additional
help from drug therapy
to sustain results from these efforts.
Most currently marketed products have been unsuccessful as treatments for
obesity" owing
to a lack of efficacy or unacceptable side-effect profiles. The most
successful drug so far was the
indirectly acting 5-hydroxytryptamine (5-HT) agonist d-fenfluramine (Reduxru)
but reports of
cardiac valve defects in up to one third of the patient population led to its
withdrawal by the FDA in
1998.
In addition, two drugs have recently been launched in the USA and Europe:
Orlistat
(XenicalTM), a drug that prevents absorption of fat by the inhibition of
pancreatic lipase, and
Sibutramine (Reductilr), a 5-HT/noradrenaline re-uptake inhibitor. However,
side effects
associated with these products may limit their long-term utility. Treatment
with XenicalTM is
reported to induce gastrointestinal distress in some patients, while
Sibutramine has been associated
with raised blood pressure in some patients.
Serotonin (5-HT) neurotransmission plays an important role in numerous
physiological
processes both in health and in psychiatric disorders. 5-HT has been
implicated in the regulation of
feeding behavior for some time. 5-HT works by inducing a feeling of fullness
or satiety so eating
stops earlier and fewer calories are consumed. It has been shown that a
stimulatory action of 5-HT
on the 5HT2C receptor plays an important role in the control of eating and in
the anti-obesity effect
of d-fenfluramine. As the 5HT2C receptor is expressed in high density in the
brain (notably in the
limbic structures, extrapyramidal pathways, thalamus and hypothalamus i.e. PVN
and DMH, and
predominantly in the choroid plexus) and is expressed in low density or is
absent in peripheral
tissues, a selective 5HT2C receptor agonist can be an effective and safe anti-
obesity agent. Also,
5HT2C knockout mice are overweight with cognitive impairment and
susceptibility to seizure thus
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
4
establishing the clear use for a 5HT2C receptor agonist in 5HT2c receptor
associated diseases or
disorders.
The 5HT2c receptor plays a role in obsessive compulsive disorder, some forms
of
depression, and epilepsy. Accordingly, 5HT2C receptor agonists can have anti-
panic properties, and
properties useful for the treatment of sexual dysfunction. In addition, 5HT2c
receptor agonists are
useful for the treatment of psychiatric symptoms and behaviors in individuals
with eating disorders
such as, but not limited to, anorexia nervosa and bulimia nervosa. Individuals
with anorexia
nervosa often demonstrate social isolation. Anorexic individuals often present
symptoms of being
depressed, anxious, obsession, perfectionistic traits, and rigid cognitive
styles as well as sexual
disinterest. Other eating disorders include, anorexia nervosa, bulimia
nervosa, binge eating disorder
(compulsive eating) and ED-NOS (i.e., eating disorders not otherwise specified
- an official
diagnosis). An individual diagnosed with ED-NOS possess atypical eating
disorders including
situations in which the individual meets all but a few of the criteria for a
particular diagnosis. What
the individual is doing with regard to food and weight is neither normal nor
healthy.
In addition, the 5HT2C receptor is also involved in other diseases, conditions
and disorders;
such as Alzheimer Disease (AD). Therapeutic agents currently prescribed for
Alzheimer's disease
(AD) are cholinomimetic agents that act by inhibiting the enzyme
acetylcholinesterase. The
resulting effect is increased levels of acetylcholine, which modestly improves
neuronal function and
cognition in patients with AD. Although, dysfunction of cholinergic brain
neurons is an early
manifestation of AD, attempts to slow the progression of the disease with
these agents have had
only modest success, perhaps because the doses that can be administered are
limited by peripheral
cholinergic side effects, such as tremors, nausea, vomiting, and dry mouth. In
addition, as AD
progresses, these agents tend to lose their effectiveness due to continued
cholinergic neuronal loss.
Therefore, there is a need for agents that have beneficial effects in AD,
particularly in
alleviating symptoms by improving cognition and slowing or inhibiting disease
progression, without
the side effects observed with current therapies. Therefore, serotonin 5HT2C
receptors, which are
exclusively expressed in brain, are attractive targets.
A major feature of AD is the formation of senile plaques made of amyloid
deposits in a
selected area of the brain. New therapies should focus on prevention of the
production of these
senile plaques. An amyloid deposit composed mainly of beta-amyloid peptide
(A(3) occupies the
plaque center. AP is a peptide of 40 to 43 residues derived from a larger
amyloid precursor protein,
APP [Selkoe DJ, et al. Ann Rev Neurosci, 1994, 17:489-517]. APP is a
ubiquitous transmembrane
glycoprotein that is present at high levels in brain cells. APP also exists as
secreted forms. By
cleavage in the A[3 region of APP, the long N-terminal fragment (secreted APP,
APPs) is secreted
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
into the extracellular space. The rate of A(3 production appears to be
inversely coupled to rate APPs
secretion. In several cell cultures, APPs secretion was accompanied by
reductions in secreted A(3
[Buxbaum JD, et al. Proc Nat Acad Sci, 1993, 90:9195-9198; Gabuzda D, et al.
JNeurochem,
1993, 61:2326-2329; Hung AY, et al. JBiol Chem, 1993, 268:22959-22962; and
Wolf BA, et al. J
5 Biol Chem, 1995, 270:4916-4922], suggesting that stimulated secretory
processing of APP into
secreted APPs is associated with reduced formation of potentially
amyloidogenic derivatives, or
plaques.
APPs is found in plasma and cerebrospinal fluid [Ghiso J, et al. Biochem
Biophys Res
Comm, 1989, 163:430-437; and Podlisny MB, et al. Biochem Biophys Res Commun,
1990,
167:1094-1101]. Considering the abundance of both membrane-bound APP and APPs,
they are
likely to have significant biological functions. Current knowledge about APP
functions indicates
APP is critically required for the maintenance of neuronal and synaptic
structure and function.
Membrane-bound APP has been suggested to have a receptor-like structure [Kang
J, et al. Nature,
1987, 325:733-736], with the cytoplasmic domain capable of complexing with a
GTP-binding
protein [Nishimoto I., et al. Nature, 1993, 362:75-79]. Membrane-embedded full-
length APP might
also have a cell adhesion function [Qiu W., et al. JNeurosci, 1995, 15:2157-
2167].
APPs has been shown to be neurotrophic and neuroprotective in vitro [Mattson
MP, et al.
Neuron, 1993, 10:243-254; and Qiu W., et al. JNeurosci, 1995, 15:2157-2167].
Other proposed
functions for APPs include the regulation of blood coagulation [Cole GM, et
al. Biochem Biophys
Res Commun, 1990, 170:288-295; Smith RP, et al. Science, 1990, 248:1126-1128;
and Van
Nostrand et al. Science, 1990, 248:745-748], wound-healing [Cunningham JM, et
al.
Histochemistfy, 1991, 95:513-517], extracellular protease activity [Oltersdorf
T, et al. Nature
(London), 1989, 341:144-147; and Van Nostrand WE, et al. Nature, 1989, 341:546-
548], neurite
extension [Jin L., et al. JNeurosci, 1994, 14:5461-5470; and Robakis NK, et
al. in Molecular
Biology ofAlzheimer's Disease. (T. Miyatake, D.J. Selkoe and Y. Ihara, ed.),
1990, pp. 179-188,
Elsevier Science Publishers B.V., Amsterdam], cell adhesiveness [Schubert D,
et al. Neuron, 1989,
3:689-694], cell growth, [Bhasin R., et al. Proc Natl Acad Sci USA, 1991,
88:10307-10311; and
Saitoh T., Cell, 1989, 58:615-622], and differentiation [Araki W., et al.
Biochem Biophys Res
Commun,1991, 181:265-271; Milward EA, et al. Neuron, 1991, 9:129-137; and
Yamamoto K, et al.
JNeurobiol, 1994, 25:585-594].
The non-selective serotonin 5HT2C agonist dexnorfenfluramine (DEXNOR)
stimulated
amyloid precursor protein (APPS) secretion in guinea pigs while reducing
levels of A(3 production
in vivo following repeat administration [Arjona A, et al. "Effect of a 5HT2C
serotonin agonist,
dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs,"
Brain Res, 2002,
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
6
951:135-140]. Guinea pigs were chosen because guinea pig and human APP exhibit
98% sequence
homology [Beck M, et al. Biochena Biophys Acta, 1997, 1351:17-21], the
proteins are processed
similarly [Beck M., et al. Neuroscience, 1999, 95:243-254], and the A(3
peptide sequences are
identical [Johnstone EM, et al. Brain Res Mol Brain Res, 1991, 10:299-305].
Although DEXNOR
is non-selective, the observed effects were attenuated by a 'selective
serotonin 5HT2C antagonist,
while a selective serotonin HT2A antagonist did not reverse the DEXNOR
effects, indicating the
serotonin 5HT2C receptors are the most relevant target for this effect.
In addition, 5-HT stimulates APPs ectodomain secretion via the serotonin 5HT2A
and
5HT2C receptors [Kitsch RM, et al. JBiol Chem, 1996, 271(8):4188-4194]. In
this study,
researchers stimulated 3T3 fibroblasts with serotonin (5-HT), which were
stably expressing
serotonin 5HT2A or 5HT2C receptors. 5-HT increased APPs secretion in a dose-
dependent manner
in both cell lines. Maximal stimulation of APPs secretion peaked at about 4-
fold. Selective
serotonin 5HT2A and 5HT2C antagonists blocked the effects in each cell line.
A serotonin 5HT2C receptor agonist can be effective for treating AD and
preventing senile
plaques. Support for this claim comes from the fact that A(3 is known to be
neurotoxic and a key
component in senile plaques involved in AD, APPs secretion and A13 levels seem
to be inversely
related, and serotonin 5HT2C agonists increase levels of APPs in vitro in cell
lines stably expressing
serotonin 5HT2C receptors while in vivo serotonin 5HT2C agonists increase
levels of APPs and
decrease levels of A(3 as measured in cerebral spinal fluid of guinea pigs.
Evidence exists supporting the use of a compound of the present invention with
agonist
activity at the serotonin 5HT2C receptor for the treatment of AD. The compound
of the invention
can be used alone or in combination with another agent or agents (such as but
not limited to AChE
inhibitors) that are typically prescribed for AD.
Another disease, disorder or condition that can is associated with the
function of the 5HT2C
receptor is erectile dysfunction (ED). Erectile dysfunction is the inability
to achieve or maintain an
erection sufficiently rigid for intercourse, ejaculation, or both. An
estimated 20-30 million men in
the United States have this condition at some time in their lives. The
prevalence of the condition
increases with age. Five percent of men 40 years of age report ED. This rate
increases to between
15% and 25% by the age of 65, and to 55% in men over the age of 75 years.
Erectile dysfunction can result from a number of distinct problems. These
include loss of
desire or libido, the inability to maintain an erection, premature
ejaculation, lack of emission, and
inability to achieve an orgasm. Frequently, more than one of these problems
presents themselves
simultaneously. The conditions may be secondary to other disease states
(typically chronic
conditions), the result of specific disorders of the urogenital system or
endocrine system, secondary
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
7
to treatment with pharmacological agents (e.g. antihypertensive drugs,
antidepressant drugs,
antipsychotic drugs, etc.) or the result of psychiatric problems. Erectile
dysfunction, when organic,
is primarily due to vascular irregularities associated with atherosclerosis,
diabetes, and hypertension.
There is evidence for use of a serotonin 5HT2C agonist for the treatment of
sexual
dysfunction in males and females. The serotonin 5HT2C receptor is involved
with the processing
and integration of sensory information, regulation of central monoaminergic
systems, and
modulation of neuroendocrine responses, anxiety, feeding behavior, and
cerebrospinal fluid
production [Tecott, L.H., et al. Nature 374: 542-546 (1995)]. In addition, the
serotonin 5HT2C
receptor has been implicated in the mediation of penile erections in rats,
monkeys, and humans.
The exact mechanism by which 5HT2C receptors mediate penile erections remains
unknown. However, there is good evidence, indirect and direct, supporting the
role of serotonin
5HT2C receptors in the mediation of penile erections. Anatomical studies have
shown that the penis
receives autonomic innervation from sympathetic and parasympathetic nuclei
located in the spinal
cord [Pescatori ES, et al. J Urol 1993; 149: 627-32]. In agreement,
experimental and clinical data
support that penile erections are controlled by a spinal reflex. A closer
analysis showed that
activation of 5HT2 spinal receptors facilitated pudendal reflex in
anesthetized cats [Danuser H and
Thor KB, Br JPhannacol 1996; 118: 150-4]. Accordingly, stimulation of 5HT2C
receptors has
been shown to be proerectile [Millan MJ, et al. European Journal
ofPhannacology 1997; 325], and
5HT2C receptors have been described on proerectile spinal parasympathetic
neurons [Bancila M et
al. Neuroscience 1999; 92: 1523-37].
Indirect evidence comes from the research and reports of the side effects
induced by the use
of selective serotonin reuptake inhibitors (SSRIs). SSRIs have demonstrated
antagonist action at
the serotonin 5HT2C receptors [Jenck et al. European Journal ofPhannacology
231: 223-229
(1993); Lightlowler et al. European Journal ofPhannacology 296: 137-43 (1996);
and Palvimaki,
E., et al. Psychophannacology 126: 234-240 (1996)]. Among the most derogatory
side effects of
SSRIs noted in humans is increased difficulty in attaining penile erection.
Although SSRIs have a
rich pharmacological profile, it is believed that the antagonist effects of
SSRIs at the 5HT2C
receptors could be implicated in the inhibition of penile erections
[Palvimaki, E., et al.
Psychopharmacology 126: 234-240 (1996)].
Further evidence comes from studies with a variety compounds with known
agonist activity
for the serotonin 5HT2C receptor. Pharmacologic studies with rats and rhesus
monkeys provide
direct evidence of the proerectile properties of agonist of the serotonin 5-
HT2C receptor [Millan MJ,
et al. European Journal of Pharnacology 1997; 325; and Pomerantz, et al.
European Journal of
Pharmacology 243:227-34 (1993)]. These pro-erectile effects were unaffected by
antagonists for
CA 02529320 2011-08-02
8
the serotonin 5HT2A and 5HT2B receptors, respectively. Antagonists of the
serotonin 5HT2C receptors
attenuated the proerectile effects of the 5-HT2c agonists. The inhibition
action corresponded to each
antagonist's affinity for the 5-HT2C receptors. In addition, agonists of the
serotonin 5HT2A and 5HT2B
receptors did not elicit penile erections.
In summary, the 5HT2C receptor is a validated and well-accepted receptor
target for the prophylaxis
and/or treatment of 5HT2C mediated receptor diseases and disorders, such as,
obesity, eating disorders,
psychiatric disorders, Alzheimer Disease, sexual dysfunction and disorders
related thereto. It can be seen
that there exists a need for selective 5HT2c receptor agonists that can safely
address these needs. The present
invention is directed to these, as well as other, important ends.
SUMMARY OF THE INVENTION
The present invention is drawn to compounds which bind to and modulate the
activity of the 5HT2C
receptor, and uses thereof. The term 5HT2c receptor as used herein includes
the human sequences found in
GeneBank accession number AF498983, naturally-occurring allelic variants,
mammalian orthologs, and
recombinant mutants thereof.
One aspect of the present invention pertains to certain substituted-2,3,4,5-
tetrahydro-3-benzazepine
derivatives as represented by Formula (I):
R3 R2
R4 \
11 N-Rt
R5 /
R6
(I)
wherein:
R1 is H or C1_8 alkyl;
R2 is C14 alkyl, -CH2-O-C1_4 alkyl, C1.4 haloalkyl or CH2OH; and
R3, R4, R5 and R6 are each independently H, C14 alkyl, amino, cyano, halogen,
C1_4
haloalkyl, nitro or OH; or
a pharmaceutically acceptable salt, hydrate and solvate thereof;
provided that when R2 is C14 alkyl, -CH2-O-C1_4 alkyl, and CH2OH then R3 and
R6
are not both hydrogen.
CA 02529320 2011-08-02
8a
Various embodiments of this invention provide a compound of Formula (I) or a
pharmaceutically
acceptable salt, hydrate, or solvate thereof:
R3 R2
Rd
I N-R,
R
R6
(1)
wherein: R1 is -H or C1_8 alkyl; R2 is C1_4 alkyl, -CH2-O-C1_4 alkyl, C1_4
haloalkyl, or -CH2OH; R4 and R5 are
5 each independently -H, C1_4 alkyl, amino, cyano, halogen, C1_4 haloalkyl,
nitro, or -OH; and (i): R3 is H; and
R6 is C1_4 alkyl, amino, cyano, halogen, C1_4 haloalkyl, nitro, or -OH; or
(ii): R3 is C1_4 alkyl, amino, cyano,
halogen, C1_4 haloalkyl, nitro, or -OH; and R6 is H; or (iii): R3 is C1_4
alkyl, amino, cyano, halogen, C1_4
haloalkyl, nitro, or -OH; and R6 is C1_4 alkyl, amino, cyano, halogen, C1_4
haloalkyl, nitro, or -OH. Also
provided are pharmaceutical compositions comprising such a compound, salt,
hydrate or solvate thereof and
a pharmaceutically acceptable carrier. Also provided is a method of producing
such a composition
comprising admixing at least one compound, salt, hydrate or solvate of this
invention and a pharmaceutically
acceptable carrier. The composition may be for use in inducing satiety, for
use in reducing food intake, for
use in controlling eating or for use in treatment of obesity.
Some embodiments of the present invention are compounds of Formula (I) wherein
the compounds
are the R enantiomers.
Some embodiments of the present invention are compounds of Formula (I) wherein
the compounds
are the S enantiomers.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
9
Another aspect of the present invention also pertains to pharmaceutical
compositions
comprising one or more compounds of the invention, and one or more
pharmaceutically acceptable
carriers.
Another aspect of the present invention pertains to methods of modulating a
5HT2C receptor
comprising contacting said receptor with a therapeutically effective amount or
dose of a compound
as described herein. Preferably, compounds of the present invention are
agonists of the 5HT2C
receptor.
Another aspect of the present invention pertains to methods of prophylaxis or
treatment of
disorders of the central nervous system; damage to the central nervous system;
cardiovascular
disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea
comprising administering to
an individual in need of such prophylaxis or treatment a therapeutically
effective amount or dose of
a compound of the present invention or a pharmaceutical composition thereof.
Another aspect of the present invention pertains to methods of decreasing food
intake of an
individual comprising administering to said individual a therapeutically
effective amount or dose of
a compound of the present invention or a pharmaceutical composition thereof.
Another aspect of the present invention pertains to methods of inducing
satiety in an
individual comprising administering to said individual a therapeutically
effective amount or dose of
a compound of the present invention or a pharmaceutical composition thereof.
Another aspect of the present invention pertains to methods of controlling
weight gain of an
individual comprising administering to said individual suffering from weight
control a
therapeutically effective amount or dose of a compound of the present
invention or a pharmaceutical
composition thereof.
Another aspect of the present invention pertains to methods of producing a
pharmaceutical
composition comprising admixing at least one compound of the present invention
and at least one
pharmaceutically acceptable carrier.
Another aspect of the present invention pertains to compounds, as described
herein, for use
in a method of treatment of the human or animal body by therapy.
Another aspect of the present invention pertains to compounds, as described
herein, for use
in a method of prophylaxis or treatment of disorders of the central nervous
system; damage to the
central nervous system; cardiovascular disorders; gastrointestinal disorders;
diabetes insipidus or
sleep apnea of the human or animal body by therapy.
Another aspect of the present invention pertains to use of compounds, as
described herein,
for the manufacture of a medicament for use in the treatment or prophylaxis of
disorders of the
central nervous system; damage to the central nervous system; cardiovascular
disorders;
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
gastrointestinal disorders; diabetes insipidus or sleep apnea.
In some embodiments, the disorders of the central nervous system are selected
the group
consisting of depression, atypical depression, bipolar disorders, anxiety
disorders, obsessive-
compulsive disorders, social phobias or panic states, sleep disorders, sexual
dysfunction, psychoses,
5 schizophrenia, migraine and other conditions associated with cephalic pain
or other pain, raised
intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-
related behavioral
disorders, behavioral disorders associated with dementia, organic mental
disorders, mental disorders
in childhood, aggressivity, age-related memory disorders, chronic fatigue
syndrome, drug and
alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual
tension. In further
10 embodiments, the disorder of the central nervous system is obesity. In
further embodiments, the
disorder of the central nervous system is Alzheimer disease. In further
embodiments, the sexual
dysfunction is Male erectile dysfunction.
In some embodiments, the damage to the central nervous system is by trauma,
stroke,
neurodegenerative diseases, toxic CNS diseases or infective CNS diseases. In
further embodiments,
the damage to the central nervous system is by encephalitis or meningitis.
In some embodiments, the cardiovascular disorder is thrombosis.
In some embodiments, the gastrointestinal disorder is dysfunction of
gastrointestinal
motility.
In some embodiments, the invention pertains to methods for alleviation of a
symptom of
any of the diseases, conditions or disorders mentioned herein.
In some embodiments, the individual is a mammal.
In some embodiments, the individual is a mammal and preferably, the mammal is
a human.
hi further embodiments, the human has a body mass index of about 18.5 to about
45.
In further embodiments, the human has a body mass index of about 25 to about
45.
In further embodiments, the human has a body mass index of about 30 to about
45.
In further embodiments, the human has a body mass index of about 35 to about
45.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
For clarity and consistency, the following definitions will be used throughout
this patent
document.
AGONISTS shall mean moieties that interact and activate the receptor, such as
the 5HT2c
receptor and initiates a physiological or pharmacological response
characteristic of that receptor. For
example, when moieties activate the intracellular response upon binding to the
receptor, or enhance GTP
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
11
binding to membranes.
The term ANTAGONISTS is intended to mean moieties that competitively bind to
the receptor
at the same site as agonists (for example, the endogenous ligand), but which
do not activate the
intracellular response initiated by the active form of the receptor, and can
thereby inhibit the
intracellular responses by agonists or partial agonists. Antagonists do not
diminish the baseline
intracellular response in the absence of an agonist or partial agonist.
CHEMICAL GROUP, MOIETY OR RADICAL:
As used herein, the term "alkyl" is intended to denote hydrocarbon compounds
including straight chain, branched and cyclic hydrocarbons, including for
example but not
limited to methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, sec-
butyl, tert-butyl,
cyclobutyl, cyclopropylmethyl, n-pentyl, isopentyl, tert-pentyl, cyclopentyl,
cyclopentylmethyl, n-hexyl, cyclohexyl, and the like. The term "C18 alkyl"
refers to an
alkyl group containing 1 to 8 carbon atoms. Likewise, the term "C1_4 alkyl"
refers to an
alkyl group containing l to 4 carbon atoms. Throughout this specification, it
should be
understood that the term alkyl is intended to encompass both non-cyclic
hydrocarbon
compounds and cyclic hydrocarbon compounds. In some embodiments of the
compounds
of the invention, alkyl groups are non-cyclic. In further embodiments, alkyl
groups are
cyclic, and in further embodiments, alkyl groups are both cyclic and
noncyclic. Where no
preference is specified, the term "alkyl" is intended to denote groups are
both cyclic and
non-cyclic.
The term "amino" denotes the group NH2.
The term "cyano" denotes the group -CN.
The term "Ci_4 haloalkyl" denotes an alkyl group, defined herein, wherein the
alkyl
is substituted with one halogen up to fully substituted and a fully
substituted C14 haloalkyl
can therefore be represented by the formula CnL2n+1 wherein L is a halogen;
when more
than one halogen is present then they may be the same or different and
selected from the
group consisting of F, Cl, Br or I. Examples of C1-4 haloalkyl groups include:
fluoromethyl,
difluoromethyl, trifluoromethyl, chlorodifluoromethyl, 2,2,2-trifluoroethyl,
pentafluoroethyl
and the like.
The term "halogen" or "halo" denotes to a fluoro, chloro, bromo or iodo group.
The term "nitro" refers to the group -NO2.
shall mean a material comprising at least two compounds or two
components; for example, and not limitation, a Pharmaceutical Composition is a
Composition.
CONTACT or CONTACTING shall mean bringing the indicated moieties together,
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
12
whether in an in vitro system or an in vivo system. Thus, "contacting" a 5HT2C
receptor with a
compound of the invention includes the administration of a compound of the
present invention to an
individual, preferably a human, having a 5HT2C receptor, as well as, for
example, introducing a
compound of the invention into a sample containing a cellular or more purified
preparation
containing a 5HT2c receptor.
IN NEED OF PROPHYLAXIS OR TREATMENT as used herein refers to a judgment
made by a caregiver (e.g. physician, nurse, nurse, practitioner, etc. in the
case of humans;
veterinarian in the case of animals, including non-human mammals) that an
individual or animal
requires or will benefit from prophylaxis or treatment. This judgment is made
based on a variety of
factors that are in the realm of a caregiver's-expertise, but that includes
the knowledge that the
individual or animal is ill, or will be ill, as the result of a disease,
condition or disorder that is
treatable by the compounds of the invention. In general, "in need of
prophylaxis" refers to the
judgment made by the caregiver that the individual will become ill. In this
context, the compounds
of the invention are used in a protective or preventive manner. However, "in
need of treatment"
refers to the judgment of the caregiver that the individual is already ill,
therefore, the compounds of
the present invention are used to alleviate, inhibit or ameliorate the
disease, condition or disorder.
INDIVIDUAL as used herein refers to any animal, including mammals, preferably
mice,
rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or
primates, and most preferably
humans.
PHARMACEUTICAL COMPOSITION shall mean a composition comprising at least one
active ingredient, whereby the composition is amenable to investigation for a
specified, efficacious
outcome in a mammal (for example, and not limitation, a human). Those of
ordinary skill in the art
will understand and appreciate the techniques appropriate for determining
whether an active ingredient
has a desired efficacious outcome based upon the needs of the artisan.
THERAPEUTICALLY EFFECTIVE AMOUNT as used herein refers to the amount of
active compound or pharmaceutical agent that elicits the biological or
medicinal response in a
tissue, system, animal, individual or human that is being sought by a
researcher, veterinarian,
medical doctor or other clinician, which includes one or more of the
following:
(1) Preventing the disease; for example, preventing a disease, condition or
disorder in an
individual that may be predisposed to the disease, condition or disorder but
does not yet experience
or display the pathology or symptomatology of the disease,
(2) Inhibiting the disease; for example, inhibiting a disease, condition or
disorder in an
individual that is experiencing or displaying the pathology or symptomatology
of the disease,
condition or disorder (i.e., arresting further development of the pathology
and/or symptomatology),
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
13
and
(3) Ameliorating the disease; for example, ameliorating a disease, condition
or disorder in
an individual that is experiencing or displaying the pathology or
symptomatology of the disease,
condition or disorder (i.e., reversing the pathology and/or symptomatology).
Compounds of the Present Invention
One aspect of the present invention pertains to certain substituted-2,3,4,5-
tetrahydro-3-
benzazepine derivatives as represented by Formula (I):
R3 R2
R4
N-R, )(XD -
R5
6
(I)
wherein:
R1 is H or C1.8 alkyl;
R2 is C1_4 alkyl, -CH2-O-C1_4 alkyl, C1_4 haloalkyl or CH2OH; and
R3, R4, R5 and R6 are each independently H, C1.4 alkyl, amino, cyano,
halogen, C1.4 haloalkyl, nitro or OH; or
a pharmaceutically acceptable salt, hydrate and solvate thereof;
provided that when R2 is C1_4 alkyl, -CH2-O-C1-4alkyl, and CH2OH then R3
and R6 are not both hydrogen.
In some embodiments, when R1 is H and R2 is CH3 then R3, R4 and R6 can not all
be
hydrogens and R5 can not be hydrogen or iso-propyl.
It is appreciated that certain features of the invention, which are, for
clarity, described in the
context of separate embodiments, may also be provided in combination in a
single embodiment.
Conversely, various features of the invention which are, for brevity,
described in the context of a
single embodiment, may also be provided separately or in any suitable
subcombination.
It is understood and appreciated that compounds of Formula (I) may have one or
more
chiral centers, and therefore can exist as enantiomers and/or diastereomers.
The invention is
understood to extend to and embrace all such enantiomers, diastereomers and
mixtures thereof,
including but not limited to racemates. Accordingly, one embodiment of the
present invention
pertains to compounds of Formula (I) and formulae used throughout this
disclosure that are R
enantiomers. Further, one embodiment of the present invention pertains to
compounds of Formula
(I) and formulae used throughout this disclosure that are S enantiomers. It is
understood that
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
14
compounds of Formula (I) and formulae used throughout this disclosure are
intended to represent
all individual enantiomers and mixtures thereof, unless stated or shown
otherwise.
In some embodiments of the present invention are compounds of Formula (I)
wherein R1 is
H. In some embodiments, compounds can be represented by Formula <(Ia) as
illustrated below:
R3 R2
R4 \
NH
R5 /
R6
(Ia)
wherein each variable in Formula (Ia) has the same meaning as described
herein, supra and is fra.
Some embodiments of the present invention are, compounds of Formula (I)
wherein R1 is
Cl_$ alkyl. In some embodiments R1 is methyl. In some embodiments, compounds
can be
represented by Formula (Ib) as illustrated below:
R3 R2
R4
N-CH3
R
5
R6
(Ib)
wherein each variable in Formula (Ib) has the same meaning as described
herein, supra and infra.
In some embodiments R1 is ethyl. In some embodiments R1 is n-propyl. In some
embodiments R1 is iso-propyl. In some embodiments R1 is n-butyl.
Some embodiments of the present invention are compounds of Formula (I) wherein
R2 is
C1-4 alkyl. In some embodiments R2 is methyl. In some embodiments, compounds
can be
represented by Formula (Ic) as illustrated below:
R3 CH3
R4
I N-RI
R
5
R6
(Ic)
wherein each variable in Formula (Ic) has the same meaning as described
herein, supra and infra.
In further embodiments R2 is ethyl. In some embodiments R2 is iso-propyl. In
some
embodiments R2 is n-butyl.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
Some embodiments of the present invention are compounds of Formula (I) wherein
R2 is
C1-4 haloalkyl. Examples of a C14 haloalkyl group include, but are not limited
to, CH2F, CHF2,
CF3, CH2CHF2, CH2CH2F, CH2CF3 and CF2CF3. In some embodiments R2 is -CF3.
Some embodiments of the present invention are compounds of Formula (I) wherein
R3 is H.
5 In some embodiments R3 is C1_4 alkyl. In some embodiments R3 is methyl
(i.e.,
-CH3).
Some embodiments of the present invention are compounds of Formula (I) wherein
R3 is
amino.
Some embodiments of the present invention are compounds of Formula (I) wherein
R3 is
10 cyano.
Some embodiments of the present invention are compounds of Formula (I) wherein
R3 is
halogen. In some embodiments R3 is a fluorine atom. In some embodiments,
compounds can be
represented by Formula (le) as illustrated below:
F R2
R4
N-R, )(XD
R5
R6
(le)
15 wherein each variable in Formula (le) has the same meaning as described
herein, supra and infra.
In some embodiments, compounds of the present invention are of Formula (le)
and R2 is C1_4 alkyl;
in further embodiments, R2 is CH3.
In some embodiments, R3 is a chlorine atom. In some embodiments, compounds can
be
represented by Formula (Ig) as illustrated below:
C1 R2
R4
I N-R,
R
5
R6
(Ig)
wherein each variable in Formula (Ig) has the same meaning as described
herein, supra and infra.
In some embodiments, compounds of the present invention are of Formula (Ig)
and R2 is C1_4 alkyl;
in further embodiments, R2 is CH3.
In some embodiments R3 is a bromine atom.
In some embodiments R3 is an iodine atom.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
16
Some embodiments of the present invention are compounds of Formula (I) wherein
R3 is
Cl-4 haloalkyl. In some embodiments R3 is CF3.
Some embodiments of the present invention are compounds of Formula (I) wherein
R3 is
nitro.
Some embodiments of the present invention are compounds of Formula (I) wherein
R3 is
-OH.
Some embodiments of the present invention are compounds of Formula (I) wherein
R4 is H.
Some embodiments of the present invention are compounds of Formula (I) wherein
R4 is
C1_4 alkyl. In some embodiments, R4 is methyl (i.e., -CH3).
Some embodiments of the present invention are compounds of Formula (I) wherein
R4 is
amino.
Some embodiments of the present invention are compounds of Formula (I) wherein
R4 is
cyano.
Some embodiments of the present invention are compounds of Formula (I) wherein
R4 is
halogen. In some embodiments R4 is a fluorine atom. In some embodiments,
compounds can be
represented by Formula (Ii) as illustrated below:
R3 R2
F
N-R1
R
5
R6
(Ii)
wherein each variable in Formula (Ii) has the same meaning as described
herein, supra and infra.
In some embodiments, compounds of the present invention are of Formula (Ii)
and R2 is C1_4 alkyl;
in further embodiments, R2 is CH3.
In some embodiments R4 is a chlorine atom. In some embodiments, compounds can
be
represented by Formula (1k) as illustrated below:
R3 R2
CI
I N-Rj
R
5
R6
(1k)
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
17
wherein each variable in Formula (1k) has the same meaning as described
herein, supra and infra.
In some embodiments, some embodiments of the present are of Formula (1k) and
R2 is C1_4 alkyl; in
further embodiments, R2 is CH3.
In some embodiments R4 is a bromine atom.
In some embodiments R4 is an iodine atom.
Some embodiments of the present invention are compounds of Formula (I) wherein
R4 is
C1_4 haloalkyl. In some embodiments R4 is CF3.
Some embodiments of the present invention are compounds of Formula (I) wherein
R4 is
nitro.
Some embodiments of the present invention are compounds of Formula (I) wherein
R4 is
-OH.
Some embodiments of the present invention are compounds of Formula (I) wherein
R5 is H.
Some embodiments of the present invention are compounds of Formula (I) wherein
R5 is
C1_4 alkyl. In some embodiments R5 is methyl (i.e., -CH3). -
Some embodiments of the present invention are compounds of Formula (I) wherein
R5 is
amino.
Some embodiments of the present invention are compounds of Formula (1) wherein
R5 is
cyano.
Some embodiments of the present invention are compounds of Formula (I) wherein
R5 is
halogen. In some embodiments R5 is a fluorine atom. In some embodiments,
compounds can be
represented by Formula (Im) as illustrated below:
R3 R2
R4
N-R,
F
R6
(Im)
wherein each variable in Formula (Im) has the same meaning as described
herein, supra and infra.
In some embodiments, compounds of the present invention are of Formula (Im)
and R2 is C1_4 alkyl;
in further embodiments, R2 is CH3.
Some embodiments of the present invention are compounds of Formula (I) wherein
R5 is
halogen. In some embodiments R5 is a chlorine atom. In some embodiments,
compounds can be
represented by Formula (Io) as illustrated below:
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
18
R3 R2
R4
N-R1
CI
R6
(Io)
wherein each variable in Formula (Io) has the same meaning as described
herein, supra and infra.
In some embodiments, compounds of the present invention are of Formula (Io)
and R2 is CI-4 alkyl;
in further embodiments R2 is CH3.
In some embodiments R5 is a bromine atom. In some embodiments R5 is an iodine
atom.
Some embodiments of the present invention are compounds of Formula (I) wherein
R5 is
C1_4 haloalkyl. In some embodiments R5 is CF3.
Some embodiments of the present invention are compounds of Formula (I) wherein
R5 is
nitro.
Some embodiments of the present invention are compounds of Formula (I) wherein
R5 is
-OH
Some embodiments of the present invention are compounds of Formula (I) wherein
R6 is H.
Some embodiments of the present invention are compounds of Formula (I) wherein
R6 is
C1.4 alkyl. In some embodiments R6 is -CH3.
Some embodiments of the present invention are compounds of Formula (I) wherein
R6 is
amino.
Some embodiments of the present invention are compounds of Formula (I) wherein
R6 is
cyano.
Some embodiments of the present invention are compounds of Formula (I) wherein
R6 is
halogen. In some embodiments R6 is a fluorine atom. In some embodiments,
compounds can be
represented by Formula (Iq) as illustrated below:
R3 R2
R4
I N-R,
R5
F
(Iq)
wherein each variable in Formula (Iq) has the same meaning as described
herein, supra and infra.
In some embodiments, compounds of the present invention are of Formula (Iq)
and R2 is C14 alkyl;
in further embodiments R2 is CH3.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
19
In some embodiments R6 is a chlorine atom. In some embodiments, compounds can
be
represented by Formula (Is) as illustrated below:
R3 R2
R4
I N-R,
R
CI
(Is)
wherein each variable in Formula (Is) has the same meaning as described
herein, supra and infra.
5 In some embodiments, compounds of the present invention are of Formula (Is)
and R2 is C1_4 alkyl
in further embodiments, R2 is C113-
In some embodiments R6 is a bromine atom. In some embodiments R6 is an iodine
atom.
Some embodiments of the present invention are compounds of Formula (I) wherein
R6 is
C1-4 haloalkyl. In some embodiments R6 is CF3.
Some embodiments of the present invention are compounds of Formula (I) wherein
R6 is
nitro.
Some embodiments of the present invention are compounds of Formula (I) wherein
R6 is
-OH.
In some embodiments, compounds of the present invention are of Formula (Ic)
wherein RI
is H or C1 8 alkyl, and R3, R4, R5, and R6 are each independently H or
halogen.
In some embodiments, compounds of the present invention are of Formula (Ic)
wherein RI
is H or CH3, and R3, R4, R5, and R6 are each independently H, F, Cl, or Br.
In some embodiments, compounds of the present invention are of Formula (Ic)
wherein RI
is H, and R3 is H, F, Cl, or Br; R4 is H or Cl; R5 is H; and R6 is H or Cl.
In some embodiments, compounds of the present invention are of Formula (Ic)
wherein RI
is CH3, and R3 is H, F, Cl, or Br; R4 is H or Cl; R5 is H; and R6 is H or Cl.
This application is related to US Provisional Patent Application, Serial No.
60/479,280,
which is incorporated by reference in its entirety.
Still further embodiments of the present invention are compounds of Formula
(I) as shown
in TABLE 2 below or a pharmaceutically acceptable salt, hydrate and solvate
thereof:
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
TABLE 2
R3 R2
R4 I N-RI
R5
R6
(I)
Rl Rz R3 R4 R5 R6
H CH3 Cl H H Cl
H CH3 Cl H Cl H
H CH3 Cl Cl H H
H CH3 Cl H H H
H CH3 H H Cl Cl
H CH3 H Cl H Cl
H CH3 Cl H H Cl
H CH3 H H H Cl
H CH3 F H H Cl
H CH3 F H Cl H
H CH3 F Cl H H
H CH3 F H H H
H CH3 H H Cl F
H CH3 H Cl H F
H CH3 Cl H H F
H CH3 H H H F
H CH3 Br Cl H H
CH3 CH3 Cl H H Cl
CH3 CH3 Cl H Cl H
CH3 CH3 Cl Cl H H
CH3 CH3 Cl H H H
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
21
R, R2 R3 R4 R5 R6
CH3 CH3 H H Cl Cl
CH3 CH3 H Cl H Cl
CH3 CH3 Cl H H Cl
CH3 CH3 H H H Cl
CH3 CH3 F H H Cl
CH3 CH3 F H Cl H
CH3 CH3 F Cl H H
CH3 CH3 F H H H
CH3 CH3 H H Cl F
CH3 CH3 H Cl H F
CH3 CH3 Cl H H F
CH3 CH3 H H H F
CH3 CH3 Cl H H Cl
CH3 CH3 Cl H Cl H
CH3 CH3 Br Cl H H
Some embodiments of the present invention are compounds of Formula (I)
selected from
the group consisting of. 6,8-Dichloro-l-methyl-2,3,4,5-tetrahydro-lH-3-
benzazepine; 6-Chloro-l-
methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; 8-Chloro-9-fluoro-l-methyl-2,3,4,5-
tetrahydro-lH--3-
benzazepine; and 8,9-Dichloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; or
a
pharmaceutically acceptable salt, hydrate and solvate thereof.
Some embodiments of the present invention are compounds of Formula (I)
selected from
the group consisting of. 6,8-Dichloro-l-methyl-2,3,4,5-tetrahydro-lH-3-
benzazepine; 6-Chloro-l-
methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; 8-Chloro-9-fluoro-l-methyl-2,3,4,5-
tetrahydro-lH--3-
benzazepine; 8,9-Dichloro-l-methyl-2,3,4,5-tetrahydro-lH--3-benzazepine; and 9-
bromo-8-chloro-l-
methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; or a pharmaceutically acceptable
salt, hydrate and
solvate thereof.
Some embodiments of the present invention are compounds of Formula (I)
selected from
the group consisting of. N-methyl-6,8-Dichloro-l-methyl-2,3,4,5-tetrahydro-lH-
3-benzazepine; N-
methyl-6-Chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; N-methyl-8-
Chloro-9-fluoro-l-
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
22
methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; N-methyl-8,9-Dichloro-l-methyl-
2,3,4,5-tetrahydro-
1H-3-benzazepine; and N-methyl-9-bromo-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-
3-benzazepine;
or a pharmaceutically acceptable salt, hydrate and solvate thereof.
Some embodiments of the present invention are compounds of Formula (I)
selected from
the group consisting of. (R)-6,8-Dichloro-l-methyl-2,3,4,5-tetrahydro-lH--3-
benzazepine; (R)-6-
Chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; (R)-8-Chloro-9-fluoro-l-
methyl-2,3,4,5-
tetrahydro-1H-3-benzazepine; (R)-8,9-Dichloro-l -methyl-2,3,4,5-tetrahydro-lH-
3-benzazepine; and
(R)-9-bromo-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; or a
pharmaceutically
acceptable salt, hydrate and solvate thereof.
Some embodiments of the present invention are compounds of Formula (I)
selected from
the group consisting of. (S)-6,8-Dichloro-l-methyl-2,3,4,5-tetrahydro-lH--3-
benzazepine; (S)-6-
Chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; (S)-8-Chloro-9-fluoro-l-
methyl-2,3,4,5-
tetrahydro-1H-3-benzazepine; (S)-8,9-Dichloro-l-methyl-2,3,4,5-tetrahydro-lH--
3-benzazepine; and
(S_)-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; or a
pharmaceutically
acceptable salt, hydrate and solvate thereof.
Some embodiments of the present invention are compounds of Formula (I)
selected from
the group consisting of: (R)-N-methyl-6,8-Dichloro-l-methyl-2,3,4,5-tetrahydro-
lH-3-benzazepine;
(R) N-methyl-6-Chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; (R)-N-
methyl-8-Chloro-9-
fluoro-1-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; (R)-N-methyl-8,9-Dichloro-
l-methyl-
2,3,4,5-tetrahydro-lH-3-benzazepine; and (R)-N-methyl-9-bromo-8-chloro-l-
methyl-2,3,4,5-
tetrahydro-1H-3-benzazepine; or a pharmaceutically acceptable salt, hydrate
and solvate thereof.
Some embodiments of the present invention are compounds of Formula (I)
selected from
the group consisting of. (S)-N-methyl-6,8-Dichloro-l-methyl-2,3,4,5-tetrahydro-
lH-3-benzazepine;
(S)-N-methyl-6-Chloro-l-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; (S)-N-
methyl-8-Chloro-9-
fluoro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine; (S)-N-methyl-8,9-Dichloro-
l-methyl-2,3,4,5-
tetrahydro-1H-3-benzazepine; and (S)-N-methyl-9-bromo-8-chloro-l-methyl-
2,3,4,5-tetrahydro-lH-
3-benzazepine; or a pharmaceutically acceptable salt, hydrate and solvate
thereof.
At various places in the present specification substituents of compounds of
the invention
are disclosed in groups or in ranges. It is specifically intended that the
invention include each and
every individual subcombination of the members of such groups and ranges. For
example, the term
"Cl-4 alkyl" is specifically intended to individually and separately disclose
methyl, ethyl, C3 alkyl
and C4 alkyl.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
23
Methods and Use
One aspect of the present invention pertains to methods of modulating a 5HTZC
receptor
comprising contacting said receptor with a therapeutically effective amount or
dose of a compound
as described herein. Preferably, compounds of the present invention are
agonists of the 5HTZC
receptor.
Another aspect of the present invention pertains to methods of prophylaxis or
treatment of a
5HTZC receptor associated disease in an individual comprising administering to
the individual in
need of such prophylaxis or treatment a therapeutically effective amount or
dose of a compound of
the present invention or a pharmaceutical composition thereof. In some
embodiments, the 5HTZC
receptor associated disease is selected from the group consisting of disorders
of the central nervous
system; damage to the central nervous system; cardiovascular disorders;
gastrointestinal disorders;
diabetes insipidus and sleep apnea. In some embodiments, the individual is a
mammal. Preferably,
the mammal is a human.
In some embodiments, the 5HTZC receptor associated related disease is selected
from the
group consisting of depression, atypical depression, bipolar disorders,
anxiety, anxiety disorders,
obsessive-compulsive disorders, social phobias, panic states, attention
deficit hyperactivity disorder,
disruptive behavior disorders, impulse control disorders, borderline
personality disorder, sleep
disorders (e.g., sleep apnea), autism, seizure disorders, mutism, selective
mutism, childhood anxiety
disorders, sexual dysfunction in males (e.g., premature ejaculation and
erectile difficulty or
dysfunction), sexual dysfunction in females, psychoses, schizophrenia,
migraine and other
conditions associated with cephalic pain or other pain, raised intracranial
pressure, epilepsy,
personality disorders, Alzheimer disease, age-related behavioral disorders,
behavioral disorders
associated with dementia, dementia of aging, organic mental disorders, mental
disorders in
childhood, aggressivity, age-related memory disorders, memory loss, chronic
fatigue syndrome,
drug and alcohol addiction, alcoholism, tobacco abuse, weight loss, obesity,
bulimia, bulimia
nervosa, anorexia nervosa, binge eating disorder, premenstrual tension,
premenstrual syndrome
(PMS or late luteal phase dysphoric disorder), post-traumatic syndrome, spinal
cord injury, damage
of the central nervous system (e.g., trauma, stroke, neurodegenerative
diseases or toxic or infective
disorders (e.g., thrombosis), gastrointestinal disorders (e.g., dysfunction of
gastrointestinal motility),
diabetes insipidus, and type II diabetes.
In some embodiments, the 5HTZC receptor associated disease is selected from
the group
consisting of high blood pressure, hypertension, high blood cholesterol,
dyslipidemia, type II (non-
insulin dependent) diabetes, insulin resistance, glucose intolerance,
hyperinsulinemia, coronary
heart disease, angina pectoris, congestive heart failure, stroke, gallstones,
cholescystitis and
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
24
cholelithiasis, gout, osteoarthritis, obstructive sleep apnea and respiratory
problems, some types of
cancer (such as endometrial, breast, prostate, and colon), complications of
pregnancy, poor female
reproductive health (such as menstrual irregularities, infertility, irregular
ovulation), bladder control
problems (such as stress incontinence), uric acid nephrolithiasis,
psychological disorders (such as
depression, eating disorders, distorted body image, and low self esteem).
In some embodiments, the 5HT2C receptor associated disease is selected from
the group
consisting of psychiatric symptoms and behaviors in individuals with eating
disorders such as, but
not limited to, anorexia nervosa and bulimia nervosa. Individuals with eating
disorders often
demonstrate social isolation. For example, anorexic individuals often present
symptoms of being
depressed, anxious, obsession, perfectionistic traits, and rigid cognitive
styles as well as sexual
disinterest. In addition to anorexia nervosa and bulimia nervosa, other eating
disorders include,
binge eating disorder (compulsive eating) and ED-NOS (i.e., eating disorders
not otherwise
specified - an official diagnosis). An individual diagnosed with ED-NOS
possess atypical eating
disorders including situations in which the individual meets all but a few of
the criteria for a
particular diagnosis. In essence, what the individual is doing with regard to
food and weight is
neither normal nor healthy.
In some embodiments, the 5HT2C receptor associated disease is selected from
the group
consisting of anorexia athletica (compulsive exercising), body dysmorphic
disorder (bigorexia),
infection-triggered auto immune subtype of anorexia in children, orthorexia
nervosa, night-eating
syndrome, nocturnal sleep-related eating disorder, rumination syndrome,
gourmand syndrome,
Prader-Willi syndrome, pica, and cyclic vomiting syndrome.
Another aspect of the present invention pertains to methods of decreasing food
intake of an
individual comprising administering to the individual a therapeutically
effective amount or dose of a
compound of the present invention or a pharmaceutical composition thereof. In
some embodiments,
the individual is a mammal. Preferably, the mammal is a human. In further
embodiments, the
human has a body mass index of about 18.5 to about 45. In further embodiments,
the human has a
body mass index of about 25 to about 45. In further embodiments, the human has
a body mass
index of about 30 to about 45. In further embodiments, the human has a body
mass index of about
to about 45.
30 Another aspect of the present invention pertains to methods of inducing
satiety in an
individual comprising administering to said individual a therapeutically
effective amount or dose of
a compound of the present invention or a pharmaceutical composition thereof.
In some
embodiments, the individual is a mammal. Preferably, the mammal is a human. In
further
embodiments, the human has a body mass index of about 18.5 to about 45. In
further embodiments,
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
the human has a body mass index of about 25 to about 45. In further
embodiments, the human has
a body mass index of about 30 to about 45. In further embodiments, the human
has a body mass
index of about 35 to about 45.
Another aspect of the present invention pertains to methods of controlling
weight gain of an
5 individual comprising administering to said individual suffering from weight
control a
therapeutically effective amount or dose of a compound of the present
invention or a pharmaceutical
composition thereof. In some embodiments, the individual is a mammal.
Preferably, the mammal
is a human. In further embodiments, the human has a body mass index of about
18.5 to about 45.
In further embodiments, the human has a body mass index of about 25 to about
45. In further
10 embodiments, the human has a body mass index of about 30 to about 45. In
further embodiments,
the human has a body mass index of about 35 to about 45.
Another aspect of the present invention pertains to methods of producing a
pharmaceutical
composition comprising admixing at least one compound of the present invention
and at least one
pharmaceutically acceptable carrier.
15 Another aspect of the present invention pertains to compounds, as described
herein, for use
in a method of prophylaxis or treatment of disorders of the central nervous
system; damage to the
central nervous system; cardiovascular disorders; gastrointestinal disorders;
diabetes insipidus or
sleep apnea of the human or animal body by therapy.
Another aspect of the present invention pertains to use of compounds, as
described herein,
20 for the manufacture of a medicament for use in the treatment or prophylaxis
of disorders of the
central nervous system; damage to the central nervous system; cardiovascular
disorders;
gastrointestinal disorders; diabetes insipidus or sleep apnea.
In some embodiments, the disorders of the central nervous system are selected
the group
consisting of depression, atypical depression, bipolar disorders, anxiety
disorders, obsessive-
25 compulsive disorders, social phobias or panic states, sleep disorders,
sexual dysfunction, psychoses,
schizophrenia, migraine and other conditions associated with cephalic pain or
other pain, raised
intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-
related behavioral
disorders, behavioral disorders associated with dementia, organic mental
disorders, mental disorders
in childhood, aggressivity, age-related memory disorders, chronic fatigue
syndrome, drug and
alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual
tension. In further
embodiments, the disorder of the central nervous system is obesity. In further
embodiments, the
disorder of the central nervous system is Alzheimer disease. In further
embodiments, the sexual
dysfunction is Male erectile dysfunction.
In some embodiments, the damage to the central nervous system is by trauma,
stroke,
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
26
neurodegenerative diseases, toxic CNS diseases or infective CNS diseases. In
further embodiments,
the damage to the central nervous system is by encephalitis or meningitis.
In some embodiments, the cardiovascular disorder is thrombosis.
In some embodiments, the gastrointestinal disorder is dysfunction of
gastrointestinal
motility.
Another aspect of the present invention pertains to methods of producing a
pharmaceutical
composition comprising admixing at least one compound of the present invention
and at least one
pharmaceutically acceptable carrier.
Another aspect of the present invention pertains to compounds, as described
herein, for use
in a method of treatment of the human or animal body by therapy.
Another aspect of the present invention pertains to compounds, as described
herein, for use
in a method of prophylaxis or treatment of disorders of the central nervous
system; damage to the
central nervous system; cardiovascular disorders; gastrointestinal disorders;
diabetes insipidus or
sleep apnea of the human or animal body by therapy.
Another aspect of the present invention pertains to use of compounds, as
described herein,
for the manufacture of a medicament for use in the treatment or prophylaxis of
disorders of the
central nervous system; damage to the central nervous system; cardiovascular
disorders;
gastrointestinal disorders; diabetes insipidus or sleep apnea.
Another aspect of the present invention pertains to the use of a compound of
the present
invention with agonist activity at the serotonin 5HT2 receptor for the
treatment and/or prophylaxis
of AD and AD related disorders. The compounds of the present invention can be
used alone or in
combination with another agent or agents (such as but not limited to AChE
inhibitors) that are
typically prescribed for AD.
Combination Therapy - Prophylaxis and Treatment
In the context of the present invention, a compound of Formula (I) or
pharmaceutical
composition thereof can be utilized for modulating the activity of the 5HT2C
receptor associated
diseases, conditions and/or disorders as described herein. Examples of
modulating the activity of
5HT2C receptor associated diseases include the prophylaxis or treatment of
obesity and/or
overweight by decreasing food intake, inducing satiation (i.e., the feeling of
fullness), controlling
weight gain, decreasing body weight and/or affecting metabolism such that the
recipient loses
weight and/or maintains weight. Such compounds and pharmaceutical compositions
can therefore
be used in the context of disorders and/or diseases where weight gain is a
component of a disease
and/or disorder such as those listed herein. Furthermore, compounds and
composition of the
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
27
present invention can be used for the prophylaxis and/or treatment of
Alzheimer Disease, erectile
dysfunction and other 5HT2C receptor associated diseases and/or disorders
described herein.
While the compounds of the invention can be administered as the sole active
pharmaceutical agent (i.e., mono-therapy), they can also be used in
combination with other
pharmaceutical agents (i.e., combination-therapy) for the treatment of the
diseases/conditions/disorders described herein. Therefore, another aspect of
the present invention
includes methods of prophylaxis and/or treatment comprising administering to
an individual in need
of prophylaxis and/or treatment a therapeutically effective amount of a
compound of the present
invention, for example Formul (I), in combination with one or more additional
pharmaceutical
agent as described herein.
Suitable pharmaceutical agents that can be used in combination with the
compounds of the
present invention include anti-obesity agents such as apolipoprotein-B
secretion/microsomal
triglyceride transfer protein (apo-B/MTP) inhibitors, MCR-4 agonists,
cholescystokinin-A (CCK-A)
agonists, serotonin and norepinephrine reuptake inhibitors (for example,
sibutramine),
sympathomimetic agensts, 03 adrenergic receptor agonists, dopamine agonists
(for example,
bromocriptine), melanocyte-stimulating hormone receptor analogs, cannabinoid 1
receptor
antagonists [for example, SR141716: N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-
(2,4-dichlorophenyl)-
4-methyl-lH-pyrazole-3-carboxamide], melanin concentrating hormone
antagonists, leptons (the
OB protein), leptin analogues, leptin receptor agonists, galanin antagonists,
lipase inhibitors (such
as tetrahydrolipstatin, i.e., Orlistat), anorectic agents (such as a bombesin
agonist), Neuropeptide-Y
antagonists, thyromimetic agents, dehydroepiandrosterone or an analogue
thereof, glucocorticoid
receptor agonists or antagonists, orexin receptor antagonists, urocortin
binding protein antagonists,
glucagon-like peptide-1 receptor agonists, ciliary neutrotrophic factors (such
as AxokineTM available
from Regeneron Pharmaceuticals, Inc., Tarrytown, NY and Procter & Gamble
Company,
Cincinnati, OH), human agouti-related proteins (AGRP), ghrelin receptor
antagonists, histamine 3
receptor antagonists or reverse agonists, neuromedin U receptor agonists,
noradrenergic anorectic
agents (for example, phentermine, mazindol and the like) and appetite
suppressants (for example,
bupropion).
Other anti-obesity agents, including the agents set forth infra, are well
known, or will be
readily apparent in light of the instant disclosure, to one of ordinary skill
in the art.
In some embodiments, the anti-obesity agents are selected from the group
consisting of
orlistat, sibutramine, bromocriptine, ephedrine, leptin, and pseudoephedrine.
In a further
embodiment, compounds of the present invention and combination therapies are
administered in
conjunction with exercise and/or a sensible diet.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
28
It will be understood that the scope of combination-therapy of the compounds
of the present
invention with other anti-obesity agents, anorectic agents, appetite
suppressant and related agents is
not limited to those listed above, but includes in principle any combination
with any pharmaceutical
agent or pharmaceutical composition useful for the treatment of overweight and
obese individuals.
Other suitable pharmaceutical agents, in addition to anti-obesity agents, that
can be used in
combination with the compounds of the present invention include agents useful
in the treatment of
concomitant diseases. For example, individuals that are over weight or obese
increase their risk of
morbidity and mortality arising from concomitant diseases, such as, but not
limited to, congestive
heart failure, type II diabetes, atherosclerosis, dyslipidemia,
hyperinsulinemia, hypertension, insulin
resistance, hyperglycemia, retinopathy, nephropathy and neuropathy. Treatment
for one or more of
the diseases cited herein include the use of one or more pharmaceutical agents
known in the art
belonging to the classes of drugs referred to, but not limited to, the
following: sulfonylureas,
meglitinides, biguanides, a-glucosidase inhibitors, peroxisome proliferators-
activated receptor-'y
(i.e., PPAR-'y) agonists, insulin, -insulin analogues, HMG-CoA reductase
inhibitors, cholesterol-
lowering drugs (for example, fibrates that include: fenofibrate, bezafibrate,
gemfibrozil, clofibrate
and the like; bile acid sequestrants which include: cholestyramine, colestipol
and the like; and
niacin), antiplatelet agents (for example, aspirin and adenosine diphosphate
receptor antagonists that
include: clopidogrel, ticlopidine and the like), angiotensin-converting enzyme
inhibitors,
angiotensin II receptor antagonists and adiponectin. In accordance to one
aspect of the present
invention, a compound of the present can be used in combination with a
pharmaceutical agent or
agents belonging to one or more of the classes of drugs cited herein.
It will be understood that the scope of combination-therapy of the compounds
of the present
invention with other pharmaceutical agents is not limited to those listed
herein, supra or infra, but
includes in principle any combination with any pharmaceutical agent or
pharmaceutical composition
useful for the treatment diseases, conditions or disorders that are linked to
overweight and obese
individuals.
Some embodiments of the present invention include methods of prophylaxis or
treatment of
a disease, disorder or condition as described herein comprising administering
to an individual in
need of such prophylaxis or treatment a therapeutically effect amount or dose
of a compound of the
present invention in combination with at least one pharmaceutical agent
selected from the group
consisting of. sulfonylureas, meglitinides, biguanides, a-glucosidase
inhibitors, peroxisome
proliferators-activated receptor-7 (i.e., PPAR-y) agonists, insulin, insulin
analogues, HMG-CoA
reductase inhibitors, cholesterol-lowering drugs (for example, fibrates that
include: fenofibrate,
bezafibrate, gemfibrozil, clofibrate and the like; bile acid sequestrants
which include:
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
29
cholestyramine, colestipol and the like; and niacin), antiplatelet agents (for
example, aspirin and
adenosine diphosphate receptor antagonists that include: clopidogrel,
ticlopidine and the like),
angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists
and adiponectin. In
some embodiments, methods of the present invention include compounds of the
present invention
and the pharmaceutical agents are administered separately. In further
embodiments, compounds of
the present invention and the pharmaceutical agents are administered together.
Suitable pharmaceutical agents that can be used in conjunction with compounds
of the
present invention include a-glucosidase inhibitors. a-Glucosidase inhibitors
belong to the class of
drugs which competitively inhibit digestive enzymes such as a-amylase,
maltase, a-dextrinase,
sucrase, etc. in the pancreas and or small intesting. The reversible
inhibition by a-glucosidase
inhibitors retard, diminish or otherwise reduce blood glucose levels by
delaying the digestion of
starch and sugars. Some representative examples of a-glucosidase inhibitors
include acarbose, N-
(1,3-dihydroxy-2-propyl)valiolamine (generic name; voglibose), miglitol, and a-
glucosidase
inhibitors known in the art.
Suitable pharmaceutical agents that can be used in conjunction with compounds
of the
present invention include sulfonylureas. The sulfonylureas (SU) are drugs
which promote secretion
of insulin from pancreatic R cells by transmitting signals of insulin
secretion via SU receptors in the
cell membranes. Examples of the sulfonylureas include glyburide , glipizide,
glimepiride and other
sulfonylureas known in the art.
Suitable pharmaceutical agents that can be used in conjunction with compounds
of the
present invention include the meglitinides. The meglitinides are benzoic acid
derivatives represent
a novel class of insulin secretagogues. These agents target postprandial
hyperglycemia and show
comparable efficacy to sulfonylureas in reducing HbAI, Examples of
meglitinides include
repaglinide, nateglinide and other meglitinides known in the art.
Suitable pharmaceutical agents that can be used in conjunction with compounds
of the
present invention include the biguanides. The biguanides represent a class of
drugs that stimulate
anaerobic glycolysis, increase the sensitivity to insulin in the peripheral
tissues, inhibit glucose
absorption from the intestine, suppress of hepatic gluconeogenesis, and
inhibit fatty acid oxidation.
Examples of biguanides include phenformin, metformin, buformin, and biguanides
known in the
art.
Suitable pharmaceutical agents that can be used in conjunction with compounds
of the
present invention include the a-glucosidase inhibitors. The a-glucosidase
inhibitors competitively
inhibit digestive enzymes such as a-amylase, maltase, a-dextrinase, sucrase,
etc. in the pancreas
and or small intestine. The reversible inhibition by a-glucosidase inhibitors
retard, diminish or
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
otherwise reduce blood glucose levels by delaying the digestion of starch and
sugars. Examples of
a-glucosidase inhibitors include acarbose, N-(1,3-dihydroxy-2-
propyl)valiolamine (generic name;
voglibose), miglitol, and a-glucosidase inhibitors known in the art.
Suitable pharmaceutical agents that can be used in conjunction with compounds
of the
5 present invention include the peroxisome proliferators-activated receptor-y
(i.e., PPAR-y) agonists.
The peroxisome proliferators-activated receptor-y agonists represent a class
of compounds that
activates the nuclear receptor PPAR-y and therefore regulate the transcription
of insulin-responsive
genes involved in the control of glucose production, transport and
utilization. Agents in the class
also facilitate the regulation of fatty acid metabolism. Examples of PPAR-y
agonists include
10 rosiglitazone, pioglitazone, tesaglitazar, netoglitazone, GW-409544, GW-
501516 and PPAR-y
agonists known in the art.
Suitable pharmaceutical agents that can be used in conjunction with compounds
of the
present invention include the HMG-CoA reductase inhibitors. The HMG-CoA
reductase inhibitors
are agents also referred to as Statin compounds that belong to a class of
drugs that lower blood
15 cholesterol levels by inhibiting hydroxymethylglutalyl CoA (HMG-CoA)
reductase. HMG-CoA
reductase is the rate-limiting enzyme in cholesterol biosynthesis. The statins
lower serum LDL
concentrations by upregulating the activity of LDL receptors and are
responsible for clearing LDL
from the blood. Some representative examples the statin compounds include
rosuvastatin,
pravastatin and its sodium salt, simvastatin, lovastatin, atorvastatin,
fluvastatin, cerivastatin,
20 rosuvastatin, pitavastatin, BMS's "superstatin", and HMG-CoA reductase
inhibitors known in the
art.
Suitable pharmaceutical agents that can be used in conjunction with compounds
of the
present invention include the angiotensin converting enzyme (ACE) inhibitors.
The angiotensin
converting enzyme inhibitors belong to the class of drugs that partially lower
blood glucose levels as
25 well as lowering blood pressure by inhibiting angiotensin converting
enzymes. Examples of the
angiotensin converting enzyme inhibitors include captopril, enalapril,
alacepril, delapril; ramipril,
lisinopril, imidapril, benazepril, ceronapril, cilazapril, enalaprilat,
fosinopril, moveltopril,
perindopril, quinapril, spirapril, temocapril, trandolapril, and angiotensin
converting enzyme
inhibitors known in the art.
30 Suitable pharmaceutical agents that can be used in conjunction with
compounds of the
present invention include the angiotensin II receptor antagonists. Angiotensin
II receptor
antagonists target the angiotensin II receptor subtype 1 (i.e., AT1) and
demonstrate a beneficial
effect on hypertension. Examples of angiotensin II receptor antagonists
include losartan (and the
potassium salt form), and angiotensin II receptor antagonists known in the
art.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
31
Other treatments for one or more of the diseases cited herein include the use
of
pharmaceutical agents known in the art belonging to the classes of drugs
referred to, but not limited
to, the following: amylin agonists (for example, pramlintide), insulin
secretagogues (for example,
GLP-1 agonists; exendin-4; insulinotropin (NN221 1); dipeptyl peptidase
inhibitors (for example,
NVP-DPP-728), acyl CoA cholesterol acetyltransferase inhibitors (for example,
Ezetimibe,
eflucimibe, and like compounds), cholesterol absorption inhibitors (for
example, ezetimibe,
pamaqueside and like compounds), cholesterol ester transfer protein inhibitors
(for example, CP-
529414, JTT-705, CETi-1, and like compounds), microsomal triglyceride transfer
protein inhibitors
(for example, implitapide, and like compounds), cholesterol modulators (for
example, NO-1886,
and like compounds), bile acid modulators (for example, GT103-279 and like
compounds) and
squalene synthase inhibitors.
Squalene synthesis inhibitors belong to a class of drugs that lower blood
cholesterol levels
by inhibiting synthesis of squalene. Examples of the squalene synthesis
inhibitors include (S)-a-
[Bis[2,2-dimethyl-l-oxopropoxy)methoxy] phosphinyl]-3-
phenoxybenzenebutanesulfonic acid,
mono potassium salt (BMS-188494) and squalene synthesis inhibitors known in
the art.
Compositions of the Present Invention
According to a further aspect, the present invention also pertains to
pharmaceutical
compositions comprising one or more compounds of Formula (I) or any formulae
disclosed herein,
and one or more pharmaceutically acceptable carriers.
Some embodiments of the present invention include a method of producing a
pharmaceutical composition comprising admixing at least one compound according
to any of the
compound embodiments disclosed herein and a pharmaceutically acceptable
carrier.
Formulations may be prepared by any suitable method, typically by uniformly
mixing the
active compound(s) with liquids or finely divided solid carriers, or both, in
the required proportions,
and then, if necessary, forming the resulting mixture into a desired shape.
Conventional excipients, such as binding agents, fillers, acceptable wetting
agents,
tabletting lubricants, and disintegrants maybe used in tablets and capsules
for oral administration.
Liquid preparations for oral administration may be in the form of solutions,
emulsions, aqueous or
oily suspensions, and syrups. Alternatively, the oral preparations may be in
the form of dry powder
that can be reconstituted with water or another suitable liquid vehicle before
use. Additional
additives such as suspending or emulsifying agents, non-aqueous vehicles
(including edible oils),
preservatives, and flavorings and colorants may be added to the liquid
preparations. Parenteral
dosage forms may be prepared by dissolving the compound of the invention in a
suitable liquid
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
32
vehicle and filter sterilizing the solution before filling and sealing an
appropriate vial or ampoule.
These are just a few examples of the many appropriate methods well known in
the art for preparing
dosage forms.
A compound of the present invention can be formulated into pharmaceutical
compositions
using techniques well known to those in the art. Suitable pharmaceutically-
acceptable carriers,
outside those mentioned herein, are known in the art; for example, see
Remington, The Science and
Practice of Pharmacy, 20th Edition, 2000, Lippincott Williams & Wilkins,
(Editors: Gennaro, A. R.,
et al.).
While it is possible that, for use in the prophylaxis or treatment, a compound
of the
invention may, in an alternative use, be administered as a raw or pure
chemical, it is preferable
however to present the compound or active ingredient as a pharmaceutical
formulation or
composition further comprising a pharmaceutically acceptable carrier.
The invention thus further provides pharmaceutical formulations comprising a
compound of
the invention or a pharmaceutically acceptable salt or derivative thereof
together with one or more
pharmaceutically acceptable carriers thereof and/or prophylactic ingredients.
The carrier(s) must be
"acceptable" in the sense of being compatible with the other ingredients of
the formulation and not
overly deleterious to the recipient thereof.
Pharmaceutical formulations include those suitable for oral, rectal, nasal,
topical (including
buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-
cutaneous and
intravenous) administration or in a form suitable for administration by
inhalation, insufflation or by
a transdermal patch. Transdermal patches dispense a drug at a controlled rate
by presenting the
drug for absorption in an efficient manner with a minimum of degradation of
the drug. Typically,
transdermal patches comprise an impermeable backing layer, a single pressure
sensitive adhesive
and a removable protective layer with a release liner. One of ordinary skill
in the art will
understand and appreciate the techniques appropriate for manufacturing a
desired efficacious
transdermal patch based upon the needs of the artisan.
The compounds of the invention, together with a conventional adjuvant,
carrier, or diluent,
may thus be placed into the form of pharmaceutical formulations and unit
dosages thereof, and in
such form may be employed as solids, such as tablets or filled capsules, or
liquids such as solutions,
suspensions, emulsions, elixirs, gels or capsules filled with the same, all
for oral use, in the form of
suppositories for rectal administration; or in the form of sterile injectable
solutions for parenteral
(including subcutaneous) use. Such pharmaceutical compositions and unit dosage
forms thereof
may comprise conventional ingredients in conventional proportions, with or
without additional
active compounds or principles, and such unit dosage forms may contain any
suitable effective
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
33
amount of the active ingredient commensurate with the intended daily dosage
range to be employed.
For oral administration, the pharmaceutical composition maybe in the form of,
for
example, a tablet, capsule, suspension or liquid. The pharmaceutical
composition is preferably
made in the form of a dosage unit containing a particular amount of the active
ingredient. Examples
of such dosage units are capsules, tablets, powders, granules or a suspension,
with conventional
additives such as lactose, mannitol, corn starch or potato starch; with
binders such as crystalline
cellulose, cellulose derivatives, acacia, corn starch or gelatins; with
disintegrators such as corn
starch, potato starch or sodium carboxymethyl-cellulose; and with lubricants
such as talc or
magnesium stearate. The active ingredient may also be administered by
injection as a composition
wherein, for example, saline, dextrose or water may be used as a suitable
pharmaceutically
acceptable carrier.
Compounds of the present invention or a solvate or physiologically functional
derivative
thereof can be used as active ingredients in pharmaceutical compositions,
specifically as 5HT2C
receptor agonists. By the term "active ingredient" is defined in the context
of a "pharmaceutical
composition" and shall mean a component of a pharmaceutical composition that
provides the
primary pharmacological effect, as opposed to an "inactive ingredient" which
would generally be
recognized as providing no pharmaceutical benefit.
The dose when using the compounds of the present invention can vary within
wide limits,
and as is customary and is known to the physician, it is to be tailored to the
individual conditions in
each individual case. It depends, for example, on the nature and severity of
the illness to be treated,
on the condition of the patient, on the compound employed or on whether an
acute or chronic
disease state is treated or prophylaxis is conducted or on whether further
active compounds are
administered in addition to the compounds of the present invention.
Representative doses of the
present invention include, but not limited to, about 0.00 1 mg to about 5000
mg, about 0.00 1 to
about 2500 mg, about 0.001 to about, 1000 mg, 0.001 to about 500 mg, 0.001 mg
to about 250 mg,
about 0.001 mg to 100 mg, about 0.001 mg to about 50 mg, and about 0.001 mg to
about 25 mg.
Multiple doses may be administered during the day, especially when relatively
large amounts are
deemed to be needed, for example 2, 3 or 4, doses. Depending on the individual
and as deemed
appropriate from the patient's physician or care-giver it may be necessary to
deviate upward or
downward from the doses described herein.
The amount of active ingredient, active salt or hydrate thereof, required for
use in treatment
will vary not only with the particular salt selected but also with the route
of administration, the
nature of the condition being treated and the age and condition of the patient
and will ultimately be
at the discretion of the attendant physician or clinician.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
34
In general, one skilled in the art understands how to extrapolate in vivo data
obtained in a
model system, typically an animal model, to another, such as a human.
Typically, animal models
include, but are not limited to, rodent models. In some circumstances, these
extrapolations may
merely be based on the weight of the animal model in comparison to another,
such as a mammal,
preferably a human, however, more often, these extrapolations are not simply
based on weights, but
rather incorporate a variety of factors. Representative factors include, but
are not limited to, the
type, age, weight, sex, diet and medical condition of the patient, the
severity of the disease, the route
of administration, pharmacological considerations such as the activity,
efficacy, pharmacokinetic
and toxicology profiles of the particular compound employed, whether a drug
delivery system is
utilized, on whether an acute or chronic disease state is being treated or
prophylaxis is conducted or
on whether further active compounds are administered in addition to the
compounds of the Formula
(I) as part of combination-therapy. The dosage regimen for treating a disease
condition with the
compounds and/or compositions of the present invention is selected in
accordance with a variety
factors as cited above. Thus, the actual dosage regimen employed may vary-
widely and therefore
may deviate from a preferred dosage regimen and one skilled in the art will
recognize that dosage
and dosage regimen outside these typical ranges can be tested and, where
appropriate, may be used
in the methods of this invention.
The desired dose may conveniently be presented in a single dose or as divided
doses
administered at appropriate intervals, for example, as two, three, four or
more sub-doses per day.
The sub-dose itself may be further divided, e.g., into a number of discrete
loosely spaced
administrations. The daily dose can be divided, especially when relatively
large amounts are
administered as deemed appropriate, into several, for example 2, 3 or 4, part
administrations. If
appropriate, depending on individual behavior, it maybe necessary to deviate
upward or downward
from the daily dose indicated.
The compounds of the present invention can be administrated in a wide variety
of oral and
parenteral dosage forms. It will be obvious to those skilled in the art that
the following dosage
forms may comprise, as the active component, either a compound of the
invention or a
pharmaceutically acceptable salt of a compound of the invention.
For preparing pharmaceutical compositions from the compounds of the present
invention,
the selection of a suitable pharmaceutically acceptable carrier can be either
solid, liquid or a mixture
of both. Solid form preparations include powders, tablets, pills, capsules,
cachets, suppositories,
and dispersible granules. A solid carrier can be one or more substances which
may also act as
diluents, flavouring agents, solubilizers, lubricants, suspending agents,
binders, preservatives, tablet
disintegrating agents, or an encapsulating material.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
In powders, the carrier is a finely divided solid which is in a mixture with
the finely divided
active component.
In tablets, the active component is mixed with the carrier having the
necessary binding
capacity in suitable proportions and compacted to the desire shape and size.
5 The powders and tablets may contain varying percentage amounts of the active
compound.
A representative amount in a powder or tablet may contain from 0.5 to about 90
percent of the
active compound; however, an artisan would know when amounts outside of this
range are
necessary. Suitable carriers for powders and tablets are magnesium carbonate,
magnesium stearate,
talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth,
methylcellulose, sodium
10 carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The
term "preparation" is
intended to include the formulation of the active compound with encapsulating
material as carrier
providing a capsule in which the active component, with or without carriers,
is surrounded by a
carrier, which is thus in association with it. Similarly, cachets and lozenges
are included. Tablets,
powders, capsules, pills, cachets, and lozenges can be used as- solid forms
suitable for oral
15 administration.
For preparing suppositories, a low melting wax, such as an admixture of fatty
acid
glycerides or cocoa butter, is first melted and the active component is
dispersed homogeneously
therein, as by stirring. The molten homogenous mixture is then poured into
convenient sized molds,
allowed to cool, and thereby to solidify.
20 Formulations suitable for vaginal administration may be presented as
pessaries, tampons,
creams, gels, pastes, foams or sprays containing in addition to the active
ingredient such carriers as
are known in the art to be appropriate.
Liquid form preparations include solutions, suspensions, and emulsions, for
example, water
or water-propylene glycol solutions. For example, parenteral injection liquid
preparations can be
25 formulated as solutions in aqueous polyethylene glycol solution. Injectable
preparations, for
example, sterile injectable aqueous or oleaginous suspensions maybe formulated
according to the
known art using suitable dispersing or wetting agents and suspending agents.
The sterile injectable
preparation may also be a sterile injectable solution or suspension in a
nontoxic parenterally
acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
Among the acceptable
30 vehicles and solvents that may be employed are water, Ringer's solution,
and isotonic sodium
chloride solution. In addition, sterile, fixed oils are conventionally
employed as a solvent or
suspending medium. For this purpose any bland fixed oil may be employed
including synthetic
mono- or diglycerides. In addition, fatty acids such as oleic acid find use in
the preparation of
injectables.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
36
The compounds according to the present invention may thus be formulated for
parenteral
administration (e.g. by injection, for example bolus injection or continuous
infusion) and may be
presented in unit dose form in ampoules, pre-filled syringes, small volume
infusion or in multi-dose
containers with an added preservative. The pharmaceutical compositions may
take such forms as
suspensions, solutions, or emulsions in oily or aqueous vehicles, and may
contain formulatory
agents such as suspending, stabilizing and/or dispersing agents.
Alternatively, the active ingredient
maybe in powder form, obtained by aseptic isolation of sterile solid or by
lyophilization from
solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free
water, before use.
Aqueous solutions suitable for oral use can be prepared by dissolving the
active component
in water and adding suitable colorants, flavours, stabilizing and thickening
agents, as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely
divided
active component in water with viscous material, such as natural or synthetic
gums, resins,
methylcellulose, sodium carboxymethylcellulose, or other well known suspending
agents.
Also included are solid form preparations which are intended to be converted,
shortly
before use, to liquid form preparations for oral administration. Such liquid
forms include solutions,
suspensions, and emulsions. These preparations may contain, in addition to the
active component,
colorants, flavors, stabilizers, buffers, artificial and natural sweeteners,
dispersants, thickeners,
solubilizing agents, and the like.
For topical administration to the epidermis the compounds according to the
invention may
be formulated as ointments, creams or lotions, or as a transdermal patch.
Ointments and creams may, for example, be formulated with an aqueous or oily
base with
the addition of suitable thickening and/or gelling agents. Lotions may be
formulated with an
aqueous or oily base and will in general also contain one or more emulsifying
agents, stabilizing
agents, dispersing agents, suspending agents, thickening agents, or coloring
agents.
Formulations suitable for topical administration in the mouth include lozenges
comprising
active agent in a flavored base, usually sucrose and acacia or tragacanth;
pastilles comprising the
active ingredient in an inert base such as gelatin and glycerin or sucrose and
acacia; and
mouthwashes comprising the active ingredient in a suitable liquid carrier.
Solutions or suspensions are applied directly to the nasal cavity by
conventional means, for
example with a dropper, pipette or spray. The formulations maybe provided in
single or multi-dose
form. In the latter case of a dropper or pipette, this may be achieved by the
patient administering an
appropriate, predetermined volume of the solution or suspension. In the case
of a spray, this may be
achieved for example by means of a metering atomizing spray pump.
Administration to the respiratory tract may also be achieved by means of an
aerosol
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
37
formulation in which the active ingredient is provided in a pressurized pack
with a suitable
propellant. If the compounds of the Formula (I) or pharmaceutical compositions
comprising them
are administered as aerosols, for example as nasal aerosols or by inhalation,
this can be carried out,
for example, using a spray, a nebulizer, a pump nebulizer, an inhalation
apparatus, a metered inhaler
or a dry powder inhaler. Pharmaceutical forms for administration of the
compounds of the Formula
(I) as an aerosol can be prepared by processes well-known to the person
skilled in the art. For their
preparation, for example, solutions or dispersions of the compounds of the
Formula (I) in water,
water/alcohol mixtures or suitable saline solutions can be employed using
customary additives, for
example benzyl alcohol or other suitable preservatives, absorption enhancers
for increasing the
bioavailability, solubilizers, dispersants and others, and, if appropriate,
customary propellants, for
example include carbon dioxide, CFC's, such as, dichlorodifluoromethane,
trichlorofluoromethane,
or dichlorotetrafluoroethane; and the like. The aerosol may conveniently also
contain a surfactant
such as lecithin. The dose of drug maybe controlled by provision of a metered
valve.
In formulations intended for administration to the respiratory tract,
including intranasal
formulations, the compound will generally have a small particle size for
example of the order of 10
microns or less. Such a particle size may be obtained by means known in the
art, for example by
micronization. When desired, formulations adapted to give sustained release of
the active
ingredient may be employed.
Alternatively the active ingredients may be provided in the form of a dry
powder, for
example, a powder mix of the compound in a suitable powder base such as
lactose, starch, starch
derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone
(PVP). Conveniently
the powder carrier will form a gel in the nasal cavity. The powder composition
may be presented in
unit dose form for example in capsules or cartridges of, e.g., gelatin, or
blister packs from which the
powder may be administered by means of an inhaler.
The pharmaceutical preparations are preferably in unit dosage forms. In such
form, the
preparation is subdivided into unit doses containing appropriate quantities of
the active component.
The unit dosage form can be a packaged preparation, the package containing
discrete quantities of
preparation, such as packeted tablets, capsules, and powders in vials or
ampoules. Also, the unit
dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be
the appropriate number of
any of these in packaged form.
Tablets or capsules for oral administration and liquids for intravenous
administration are
preferred compositions.
The compounds according to the invention may optionally exist as
pharmaceutically
acceptable salts including pharmaceutically acceptable acid addition salts
prepared from
CA 02529320 2011-08-02
38
pharmaceutically acceptable non-toxic acids including inorganic and organic
acids. Representative acids
include, but are not limited to, acetic, benzenesulfonic, benzoic,
camphorsulfonic, citric, ethenesulfonic,
dichloroacetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic,
hydrochloric, isethionic, lactic,
maleic, malic, mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic,
pantothenic, phosphoric, succinic,
sulfiric, tartaric, oxalic, p-toluenesulfonic and the like, such as those
pharmaceutically acceptable salts listed
in Journal of Pharmaceutical Science, 66, 2 (1977).
The acid addition salts may be obtained as the direct products of compound
synthesis. In the
alternative, the free base may be dissolved in a suitable solvent containing
the appropriate acid, and the salt
isolated by evaporating the solvent or otherwise separating the salt and
solvent. The compounds of this
invention may form solvates with standard low molecular weight solvents using
methods known to the
skilled artisan.
Compounds of the present invention can be converted to "pro-drugs." The term
"pro-drugs" refers
to compounds that have been modified with specific chemical groups known in
the art and when
administered into an individual these groups undergo biotransformation to give
the parent compound. Pro-
drugs can thus be viewed as compounds of the invention containing one or more
specialized non-toxic
protective groups used in a transient manner to alter or to eliminate a
property of the compound. In general,
the "pro-drug" approach is utilized to facilitate oral absorption. A thorough
discussion is provided in T.
Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the
A.C.S. Symposium Series, and
in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American
Pharmaceutical Association and
Pergamon Press, 1987.
Some embodiments of the present invention include a method of producing a
pharmaceutical
composition for "combination-therapy" comprising admixing at least one
compound according to any of the
compound embodiments disclosed herein, at least one pharmaceutical agent as
described herein and a
pharmaceutically acceptable carrier.
In some embodiments the pharmaceutical agents is selected from the group
consisting of:
apolipoprotein-B secretion/microsomal triglyceride transfer protein (apo-
B/MTP) inhibitors, MCR-4 agonists,
cholescystokinin-A (CCK-A) agonists, serotonin and norepinephrine reuptake
inhibitors (for example,
sibutramine), sympathomimetic agensts, (33 adrenergic receptor agonists,
dopamine agonists (for example,
bromocriptine), melanocyte-stimulating hormone receptor analogs, cannabinoid 1
receptor antagonists [for
example, SR141716: N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-lH-pyrazole-3-
carboxamide], melanin concentrating hormone antagonists, leptons (the OB
protein), leptin analogues, leptin
receptor agonists, galanin antagonists,
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
39
lipase inhibitors (such as tetrahydrolipstatin, i.e., Orlistat), anorectic
agents (such as a bombesin
agonist), Neuropeptide-Y antagonists, thyromimetic agents,
dehydroepiandrosterone or an analogue
thereof, glucocorticoid receptor agonists or antagonists, orexin receptor
antagonists, urocortin
binding protein antagonists, glucagon-like peptide-1 receptor agonists,
ciliary neutrotrophic factors
(such as AxokineTM), human agouti-related proteins (AGRP), ghrelin receptor
antagonists,
histamine 3 receptor antagonists or reverse agonists, neuromedin U receptor
agonists, noradrenergic
anorectic agents (for example, phentermine, mazindol and the like) and
appetite suppressants (for
example, bupropion). In further embodiments, the pharmaceutical agent is
selected from the group
consisting of orlistat, sibutramine, bromocriptine, ephedrine, leptin, and
pseudoephedrine.
In some embodiments the pharmaceutical agents is selected from the group
consisting of:
sulfonylureas, meglitinides, biguanides, a-glucosidase inhibitors, peroxisome
proliferators-activated
receptor-y (i.e., PPAR-y) agonists, insulin, insulin analogues, HMG-CoA
reductase inhibitors,
cholesterol-lowering drugs (for example, fibrates that include: fenofibrate,
bezafibrate, gemfibrozil,
clofibrate and the like; bile acid sequestrants which include: cholestyramine,
colestipol and the like;
and niacin), antiplatelet agents (for example, aspirin and adenosine
diphosphate receptor antagonists
that include: clopidogrel, ticlopidine and the like), angiotensin-converting
enzyme inhibitors,
angiotensin II receptor antagonists and adiponectin.
It is noted that when the 5HT2C receptor agonists are utilized as active
ingredients in a
pharmaceutical composition, these are not intended for use only in humans, but
in other non-human
mammals as well. Indeed, recent advances in the area of animal health-care
mandate that
consideration be given for the use of 5HT2C receptor agonists for the
treatment of obesity in
domestic animals (e.g., cats and dogs), and 5HT2c receptor agonists in other
domestic animals
where no disease or disorder is evident (e.g., food-oriented animals such as
cows, chickens, fish,
etc.). Those of ordinary skill in the art are readily credited with
understanding the utility of such
compounds in such settings.
Preparation of Compounds of the Invention
In the illustrated syntheses outlined below, the labeled substituents have the
same
identifications as set out in the definitions of the compounds of the present
invention of Formula (I)
and the Formulae of the subgenera as described herein.
Those of skill in the art will appreciate the wide variety of compounds of the
present
invention can be prepared according to Schemes I through V, Infra. One
representative synthesis is
set forth below in Scheme I, for when R2 is methyl:
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
Scheme I
R3 R3
R4 I Acylation R4 i::o Iodination
RS NH2 R5 H CF3
R6 R6
A B
R3 R3
R4 I r, Allylation R4 I i X Heck Rxn
R5 H CF3 R5 N
RS RS O11
C D
R3 R3
Ra No Hydrogenation R4 No Substitution
R5 CF3 RS CF3
R6 R6
E F
R3 R3
R4 o Deprotection R4 N-Alkylation
I N- I NH
RS CF3 R5
R6 R6
5 G H
By utilizing, for example, an appropriately substituted 2-phenyl ethylamino
Compound A
having any of a wide variety of substituents R3, R4, R5 and R6 the
corresponding substituted 1-
methyl-2,3,4,5-tetrahydro-lH-3-benzazepine (Compound H) can be prepared. In a
subsequent step,
Compound H can be readily alkylated by, for example, treatment with excess
formaldehyde or
10 formaldehyde equivalent such as paraformaldehyde (for methylation) or a
higher order aldehyde,
followed by reduction with NaBH3CN or similar reducing agent according to
methodologies known
in the art.
In addition, numerous synthetic transformations can be performed at different
stages in the
pathway illustrated in Scheme I to prepare additional compounds of Formula
(I). For example,
15 Compound E can be converted into a number of compounds of the invention
including, R2 =
-CH2OH. In this case, the double bond of Compound E can be hydroborated using
methods known
in the art, such as diborane, disiamylborane and the like, to give a primary
alcohol after oxidative
workup (i.e., H202). Either the N-protection can be removed to give desired
compounds of the
invention or the primary alcohol can be subsequently converted to an ether
using methods known in
20 the art such as, for example, the Williamson ether procedure, using an
alkyl halide in the presence
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
41
of a base. In this example, the N-protection can be removed to give compounds
of Formula (I)
wherein R2 is the group CH2O-C1-4 alkyl. Alternatively, the primary alcohol
can be fluorinated
using reagents known in the art, such as dialkylaminosulfur trifluorides and
the like. Certain
dialkylaminosulfur trifluorides include, but not limited to, bis(2-
methoxyethyl)amino-sulfur
trifluoride, (diethylamino)sulfur trifluoride, (dimethylamino)sulfur
trifluoride, morpholinosulfur
trifluoride and the like. Treatment with a fluorinating agent can give
monofluoroalkyl compounds
of Formula (I), wherein R2 is -CH2F. In addition, the primary alcohol prepared
from Compound E
can be further oxidized to give the corresponding aldehyde and in a similar
manner subsequently
converted to difluoroalkyl compounds of Formula (I), wherein R2 is -CHF2.
Reaction Scheme II is provided below showing these illustrative
transformations and is not
intended to be limiting:
Scheme II
O-C14alkyl
OH
R3 R4 O O H F F
N4 R4 )(561 O Rs CF3 R F3 F
R5
R6 R6
E
Another representative synthetic pathway for the preparation of compounds of
Formula (I)
is set forth below in Reaction Scheme III:
Scheme III:
R3 R3
R4 I Acylation R4 I L 0 Cyclization
Rs / NH2 Rs H/LJ
Rs R6 R2
A K
R3 R2 O R3 R2
R4 Reduction R4 N-Alkylation 11- I / NH )(X N
H
Rs Rs
D
R6 R6
L (Ia)
CA 02529320 2011-08-02
42
By utilizing, for example, an appropriately substituted 2-phenyl ethylamino
Compound A having
any of a wide variety of substituents R3, R4, R5 and R6 the corresponding 1-
substituted-2,3,4,5-
tetrahydro-1H-3-benzazepine [i.e., a compound of Formula (Ia)] can be
prepared. Scheme III illustrates
one general pathway for the introduction of R2 groups into the compounds of
the present invention.
Compound A is acylated with a carboxylic acid derivative using one of the many
methods, such as one of
the commonly known coupling agents, available to the artisan. A particularly
useful method uses an acid
chloride as described in the Examples, Infra. The carboxylic acid derivative
is selected to possess a
leaving group or a moiety that can be converted into a leaving group (i.e.,
Lg). The resulting Compound
K is cyclized in the presence of a Lewis Acid, such as, for example, aluminum
chloride. After reduction,
compounds of the invention are obtained wherein Rl is H [i.e., a compound of
Formula (Ia)].
One alternate synthetic approach that can be used to prepare compounds of the
present invention
utilizes Compound L (i.e., R2 is H). In this method, the amide nitrogen is
first alkylated (providing the
Rl group, Compound N) or protected (i.e., Compound 0) using any number of the
methods known in the
art. The R2 group is subsequently introduced via an alkylation reaction to
provide Compounds P and Q
respectively. Alkylation reactions can be conducted under basic conditions,
for example, using
DMF/NaH, and an alkylating agent of the formula R2-Lg (wherein: R2 has the
same meaning as described
herein and Lg is a leaving group known in the art, such as, Cl, Br, I, OMs,
OTs and the like). Examples
of the alkylating agent include, but are not limited to, CH3I, CH3OMs, CH3OTs,
CH3CH2I, CF3CH2I,
CF3I, CH3OCH2C1 and the like. A representative alkylation example has been
reported by Orito, K. and
Matsuzaki, T. in Tetrahedron, 1980, 36, 81, 1017-1021. In the example when the
nitrogen is protected
(i.e., Compound Q), the protecting group is first removed and the amide
reduced to provide compounds
of the invention wherein Rl is H. In the example where the nitrogen is
alkylated (i.e., Compound P),
then the amide is merely reduced to provide compounds wherein R, is alkyl.
This method is illustrated in
Schemes IV and V below:
Scheme IV
R3 O R3 O R3 R2 O
R4 # R4 \ R4
NH ON / N-R, N N-Rj
R5 R5 R5
Rs R6 R6
L (R2 is H) N P
CA 02529320 2011-08-02
43
Scheme V
R3 O R3 O R3 R2 O
R4 NH 0 R4 I \ R4 \
N p ~ 00
R5 R5 R5
R6 L (R2 is H) R6 2 R6 2
where: `.J is a protecting group
Those of skill in the art will appreciate that a wide variety of compounds of
the present invention
can be prepared according to Schemes I through V.
Protecting groups may be required for various functionality or functionalities
during the
synthesis of some of the compounds of the invention. Accordingly,
representative protecting groups that
are suitable for a wide variety of synthetic transformations are disclosed in
Greene and Wuts, Protective
Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York, 1999.
As described herein, compounds of the present invention can exist in various
forms, for example,
enantiomers and racemates. In is understood that the optically active forms
can be obtained by resolution
of the racemates, separated by chiral chromatography or by asymmetric
synthesis using methods known
in the art to obtain enantiomers.
Other Utilities
Another object of the present invention relates to radio-labeled compounds of
Formula (I) that
would be useful not only in radio-imaging but also in assays, both in vitro
and in vivo, for localizing and
quantitating the 5HT2c receptor in tissue samples, including human, and for
identifying 5HT2c receptor
ligands by inhibition binding of a radio-labeled compound. It is a further
object of this invention to develop
novel 5HT2c receptor assays of which comprise such radio-labeled compounds.
The present invention embraces isotopically-labeled compounds of Formula (I)
and any subgenera
herein, such as but not limited to, Formula (Ia) through Formula (Is). An
"isotopically" or "radio-labeled"
compounds are those which are identical to compounds disclosed herein, but for
the fact that one or more
atoms are replaced or substituted by an atom having an atomic mass or mass
number different from the
atomic mass or mass number typically found in nature (i.e., naturally
occurring). Suitable radionuclides that
may be incorporated in compounds of the present invention include but are not
limited to 2H (also written as
D for deuterium), 3H (also written as T for tritium), 11C, 13C 14C 13N 15N 150
170 18Q 18F 35S, 36Cl, 82Br,
75Br, 76Br, 77Br, 1231 1241 1251 and 1311. The radionuclide that is
incorporated in the instant radio-labeled
compounds will depend
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
44
on the specific application of that radio-labeled compound. For example, for
in vitro 5HT2C
receptor labeling and competition assays, compounds that incorporate 3H, 14C,
82Br, 1251, 1311, 35S or
will generally be most useful. For radio-imaging applications 11C, 18F, 1251,
1231, 1241, 131I, 75Br, 76Br
or 77Br will generally be most useful.
It is understood that a "radio-labeled " or "labeled compound" is a compound
of Formula
(I) that has incorporated at least one radionuclide; in some embodiments the
radionuclide is selected
from the group consisting of 3H, 14C, 1251, 35S and 82Br.
Certain isotopically-labeled compounds of the present invention are useful in
compound
and/or substrate tissue distribution assays. In some embodiments the
radionuclide 3H and/or 14C
isotopes are useful in these studies. Further, substitution with heavier
isotopes such as deuterium
(i.e., 2H) may afford certain therapeutic advantages resulting from greater
metabolic stability (e.g.,
increased in vivo half-life or reduced dosage requirements) and hence maybe
preferred in some
circumstances. Isotopically labeled compounds of the present invention can
generally be prepared
by following procedures analogous to those disclosed in the Schemes supra and
Examples infra, by
substituting an isotopically labeled reagent for a non-isotopically labeled
reagent. Other synthetic
methods that are useful are discussed infra. Moreover, it should be understood
that all of the atoms
represented in the compounds of the invention can be either the most commonly
occurring isotope
of such atoms or the more scarce radio-isotope or nonradio-active isotope.
Synthetic methods for incorporating radio-isotopes into organic compounds are
applicable
to compounds of the invention and are well known in the art. These synthetic
methods, for
example, incorporating activity levels of tritium into target molecules, are
as follows:
A. Catalytic Reduction with Tritium Gas - This procedure normally yields high
specific
activity products and requires halogenated or unsaturated precursors.
B. Reduction with Sodium Borohydride [3H] - This procedure is rather
inexpensive and
requires precursors containing reducible functional groups such as aldehydes,
ketones, lactones,
esters, and the like.
C. Reduction with Lithium Aluminum Hydride [3H ] - This procedure offers
products at
almost theoretical specific activities. It also requires precursors containing
reducible functional
groups such as aldehydes, ketones, lactones, esters, and the like.
D. Tritium Gas Exposure Labeling - This procedure involves exposing precursors
containing exchangeable protons to tritium gas in the presence of a suitable
catalyst.
E. N-Methylation using Methyl Iodide [3H] - This procedure is usually employed
to
prepare O-methyl or N-methyl (H) products by treating appropriate precursors
with high specific
activity methyl iodide N. This method in general allows for higher specific
activity, such as for
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
example, about 70-90 Ci/mmol.
Synthetic methods for incorporating activity levels of 1251 into target
molecules include:
A. Sandmeyer and like reactions - This procedure transforms an aryl or
heteroaryl amine
into a diazonium salt, such as a tetrafluoroborate salt, and subsequently to
125I labeled compound
5 using Na 1251. A represented procedure was reported by Zhu, D.-G. and co-
workers in J. Org. Chem.
2002, 67, 943-948.
B. Ortho 125lodination of phenols - This procedure allows for the
incorporation of 125I at
the ortho position of a phenol as reported by Collier, T. L. and co-workers in
J. Labeled Compd
Radiopharm. 1999, 42, S264-S266.
10 C. Aryl and heteroaryl bromide exchange with 125I - This method is
generally a two step
process. The first step is the conversion of the aryl or heteroaryl bromide to
the corresponding tri-
alkyltin intermediate using for example, a Pd catalyzed reaction [i.e.
Pd(Ph3P)4] or through an aryl
or heteroaryl lithium, in the presence of a tri-alkyltinhalide or
hexaalkylditin [e.g.,
(CH3)3SnSn(CH3)3]. A represented procedure was reported by Bas, M.-D. and co-
workers in J.
15 Labeled Compd Radiopharm. 2001, 44, S280-S282.
A radio-labeled 5HT2C receptor compound of Formula (I) can be used in a
screening assay
to identify/evaluate compounds. In general terms, a newly synthesized or
identified compound (i.e.,
test compound) can be evaluated for its ability to reduce binding of the
"radio-labeled compound of
Formula (I)" to the 5HT2C receptor. Accordingly, the ability of a test
compound to compete with
20 the "radio-labeled compound of Formula (I)" for the binding to the 5HT2C
receptor directly
correlates to its binding affinity.
The labeled compounds of the present invention bind to the 5HT2C receptor. In
one
embodiment the labeled compound has an IC50 less than about 500 M, in another
embodiment the
labeled compound has an IC50 less than about 100 M, in yet another embodiment
the labeled
25 compound has an IC50 less than about 10 M, in yet another embodiment the
labeled compound has
an IC50 less than about 1 M, and in still yet another embodiment the labeled
inhibitor has an IC50
less than about 0.1 pM.
Other uses of the disclosed receptors and methods will become apparent to
those in the art
based upon, inter alia, a review of this disclosure.
30 As will be recognized, the steps of the methods of the present invention
need not be
performed any particular number of times or in any particular sequence.
Additional objects,
advantages, and novel features of this invention will become apparent to those
skilled in the art
upon examination of the following examples thereof, which are intended to be
illustrative and not
intended to be limiting.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
46
EXAMPLES
Example 1
Intracellular IP3 Accumulation Assay:
HEK293 cells were transfected in 15cm sterile dishes with or without (control)
16ug of
human 5HT2C receptor cDNA [for example see, Saltzman, A. G., et al. Biochem.
Biophys. Res.
Commun. 181, 1469-1478 (1991)] using 25ul of lipofectamine. Cells were then
incubated for 3-4
hours at 37 C/5%CO2 and then transfection media was removed and replaced with
100ul of
DMEM. Cells were then plated onto 100cm sterile dishes. The next day cells
were plated into 96
well PDL microtiter plates at a density of 55K/0.2m1. Six hours latter, media
was exchanged with
[3H]inositol (0.25 uCi/well) in inositol free DMEM and plates were incubated
at 37 C/5%CO2
overnight. The next day, wells were aspirated and 200u1 of DMEM containing
test compound,
IOuM pargyline, and 10niM LiC1 was added to appropriate wells. Plates were
then incubated at
37 C/5%CO2 for three hours followed aspiration and by addition of fresh ice
cold stop solution (1M
KOH, 19mM Na-borate, 3.8 mM EDTA) to each well. Plates were kept on ice for 5-
10 min and the
wells were neutralized by addition of 200ul of fresh ice cold neutralization
solution (7.5% HCI).
Plates were then frozen until further processing is desired. The lysate was
then transferred into 1.5
ml Eppendorf tubes and 1 ml of chloroform/methanol (1:2) was added/tube. The
solution was
vortexed for 15 seconds and the upper phase was applied to a Biorad AG1-X8TM
anion exchange
resin (100-200 mesh). First, the resin was washed with water at 1:1.25 W/V and
0.9 ml of upper
phase was loaded onto the column. The column was then washed with 10 ml of 5
mM myo-inositol
and 10 ml of 5 mM Na-borate/60mM Na-formate. The inositol tris phosphates were
eluted into
scintillation vials containing 10 ml of scintillation cocktail with 2 ml of
0.1 M formic acid/ 1 M
ammonium formate. The columns were regenerated by washing with 10 ml of 0.1 M
formic
acid/3M ammonium formate and rinsed twice with dd H2O and stored at 4 C in
water.
The biological activities in the IP Accumulation Assay for several
representative
compounds are shown in Table 3 below:
Table 3
5HT2C (IC50)
Compound No. IP Accumulation Assay (nM)
1 11.7
3 24.5
The majority of the compounds of the Examples showed activities in the IP
Accumulation
Assay in the range between about 11 nM and about 5 pM.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
47
Example 2
Inhibition of food intake in food-deprived rats
Male Sprague-Dawley rats (250-350g) are deprived of food overnight prior to
testing. Prior
to food deprivation, the animals are weighed and separated into treatment
groups in order to balance
groups according to body weight. On the test day, animals are placed into
individual cages (no
bedding) at 9:00am with free access to water. At 10:00am, animals are injected
with test compound
(p.o., i.p., or s.c.) and then presented with a pre-weighed amount of food in
a dish either 60 min
(p.o.) or 30 min (i.p. and s.c.) after drug administration. Food consumption
over different time
points is determined by weighing the food cup at 1, 2, 4, and 6 hr after the
food is presented. Thus,
food consumption is measured at 2, 3, 5, and 7 hr post-injection in p.o.
studies, and at 1.5; 2.5, 4.5,
and 6.5 hr post-injection in i.p. and s.c. studies.
Example 3
Syntheses of Selected Compounds of the Invention
Example 3.1: Preparation of (R,S) 6,8-Dichloro-l-methyl-2,3,4,5-tetrahydro-1H-
3-
benzazepine (Also referred to herein as Compound 1).
CI
""PtIN
CI
Step 1: Preparation of 2-chloro-N-[2-(2,4-dichlorophenyl)ethyl]propionamide.
A solution of 2,4-dichlorophenethylamine (1.0 g, 5.3 mmol) in dichloromethane
(20 mL)
was treated with diisopropylethylamine (0.82 g, 6.3 mmol) and 2-
chloropropionylchloride (0.67
mL, 5.3 mmol) sequentially, and stirred at 20 C for 4 hours. The mixture was
diluted with
dichloromethane (50 mL), washed with 10% aqueous HCl, brine (20 mL), dried
with Na2SO4 and
concentrated, resulting in 1.5 g of the desired product as a brown oil. MS
calculated for
C11H12C13NO+H: 280, observed: 280.
Step 2: Preparation of 6,8-dichloro-l-methyl-2-oxo-2,3,5-trihydro-lH-3-
benzazepine.
Neat 2-Chloro-N-[2-(2,4-dichlorophenyl)ethyl]propionamide (2.5 g, 9.1 mmol)
and AIC13
(3.6 g, 27 mmol) were heated at 150 C for 18 hours while stirring. The product
mixture was
quenched with water (10 mL), diluted with dichloromethane (100 mL), the
organic phase separated,
washed with brine (50 mL), dried with Na2SO4 and concentrated, resulting in
1.9 g of a brown oil.
MS calculated for C11H11C12NO+H: 244, observed: 244.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
48
Step 3: Preparation of 6,8-dichloro-l-methyl-2,3,4,5-tetrahydro-lH-3-
benzazepine.
A solution of 6,8-Dichloro-l-methyl-2-oxo-2,3,5-trihydro-lH-3-benzazepine (1.9
g, 7.8
mmol) in tetrahydrofuran (50 mL) was treated with 1.0 M borane in THE (20.0
mL, 20.0 mmol),
and stirred at 20 C for 5 hours. The mixture was quenched with methanol (10
mL), acidified with
concentrated HCl (0.2 mL), azeotroped with methanol (3 x 100 nil-) and
concentrated. Flash
chromatography (5% methanol in dichloromethane) resulted in 1.0 g of a clear
oil. 1H NMR (400
MHz, CDC13) S 7.20 (s, 1 H), 6.90 (s, 1 H), 4.30 (bs, 1 H), 3.92 (m, 1 H),
3.51 (m, 1 H), 3.37 (m, 2
H), 3.03 (m, 1 H), 2.77 (m, 2 H), 1.31 (d, J=8 Hz, 3 H). MS calculated
for`C11H13C12N+H: 230,
observed: 230.
Example 3.2: Preparation of (R,S) 6-Chloro-l-methyl-2,3,4,5-tetrahydro-lH--3-
benzazepine
(Compound 2).
~. / NH
CI
Compound 2 was prepared utilizing a similar procedure as described for the
preparation of
Compound 1. (R,S) 6-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine was
obtained from 2-
chlorophenethylamine as a colorless oil. 1H NMR (400 MHz, CDC13) 6 7.17 (d,
J=8 Hz, 1 H), 6.93
(m, 2 H), 3.97 (bs, 1 H), 3.79 (m, 1 H), 3.3-3.1 (m, 3 H), 2.95 (d, J=11 Hz, 1
H), 2.8-2.6 (m, 2 H),
1.3 (d, J=8 Hz, 3 H). MS calculated for C11H14C1N+H: 196, observed: 196.
Example 3.3: Preparation of (R,S) 8-Chloro-9-fluoro-l-methyl-2,3,4,5-
tetrahydro-lH-3-
benzazepine (Compound 3).
F
CI
NH
Step 1: Preparation of N-Trifluoroacetyl-8-chloro-9-fluoro-l-methyl-2,3,4,5-
tetrahydro-1 H-3-b enzazepine.
A solution of N-trifluoroacetyl-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-
benzazepine (2.5
g, 8.5 mmol) in 1,2-dichloroethane (15 mL) was treated with Selectfluor (3.9
g, 11 mmol),
trifluoromethanesulfonic acid (8 mL, 90 mmol) and stirred 60 hours at 75 C.
The product mixture
was poured into water (200 nL), extracted with EtOAc (200 mL), the organic
phase washed with
saturated aqueous NaHCO3 (2 x 100 mL), brine (100 mL), dried with Na2SO4 and
concentrated.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
49
The crude product was purified by flash chromatography (6 % EtOAc in hexane,
silica) resulting in
0.6 g of a white solid. MS calculated for C13H12C1F4NO+H: 310, observed: 310.
Step 2: Preparation of 8-Chloro-9-fluoro-l-methyl-2,3,4,5-tetrahydro-1H-3-
benzazepine.
A solution ofN-trifluoroacetyl-8-chloro-9-fluoro-l-methyl-2,3,4,5-tetrahydro-
lH-3-
benzazepine (160 mg, 0.22 mmol) in methanol (3 mL) was treated with 15%
aqueous NaOH (2
mL), and stirred for 3.5 hours at 25 C. The product mixture was concentrated,
extracted 3 times
with CH2C12 (5 mL), dried with Na2SO4 and concentrated to give 93 mg of a
clear oil. 1H NMR
(400 MHz, CDC13) 6 7.06 (dd, J=8, 8 Hz, 1 H), 6.75 (d, J=8 Hz, 1 H), 3.58 (m,
1 H), 3.25-3.15 (m,
3 H), 2.93 (d, J=13 Hz, 1 H) 2.75-2.60 (m, 3H), 1.96 (bs, 1 H), 1.33 (d, J=8
Hz, 3 H). MS
calculated for C11H13CIFN+H: 214, observed: 214.
Example 3.4: Preparation of (R,S) 8,9-Dichloro-l-methyl-2,3,4,5-tetrahydro-lH-
3-
benzazepine (Compound 4).
CI
CI
NH
Compound 4 was prepared utilizing a similar procedure as described herein for
the
preparation of Compound 1. (R,S) 8,9-dichloro-l-methyl-2,3,4,5-tetrahydro-lH-3-
benzazepine was
obtained from 3,4-dichlorophenethylamine as a colorless oil. 1H NMR (400 MHz,
CDC13) S 7.40
(d, J=8 Hz, 1 H), 7.16 (d, J=8 Hz, 1 H), 4.17 (m, 1 H), 3.55 (m, 2 H), 3.5-3.3
(m, 2 H), 3.2-3.0 (m,
2 H), 1.43 (d, J=7 Hz, 3 H). MS calculated for C11H13C12N+H: 230, observed:
230.
Example 3.5: Preparation of (S)-8,9-dichloro-l-methyl-2,3,4,5-tetrahydro-1H-3-
benzazepine
(Compound 5).
CI
CI
NH
Step 1: Preparation of (S)-N-Trifluoroacetyl-8=chloro-l-methyl-2,3,4,5-
tetrahydro-
1H-3-benzazepine.
(S)-N-Trifluoroacetyl-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine
was prepared
from (S)-8-chloro-l-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine utilizing a
similar procedure as
described herein for the preparation of Compound 7 (one exception is that the
resolution step was
performed using D-tartaric acid). 1H NMR (400 MHz, CDC13, mixture of rotamers)
8 7.27 (m, 1H),
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
6.96 (m, 111), 4.26 (bm, 0.6H), 4.19-4.03 (m, 1.7H), 3.92-3.87 (m, 0.8H) 3.75-
3.69 (m, 0.8H),
3.47-3.22 (m, 2H), 2.91 (m, 1H), 1.28-1.25 (m, 3H). MS calculated for
C13H13C1F3NO+H: 292,
observed: 292.
Step 2: Preparation of (S)-N-Trifluoroacetyl-8,9-dichloro-l-methyl-2,3,4,5-
5 tetrahydro-lH-3-benzazepine.
A solution of (S)-N-Trifluoroacetyl-8-chloro-l-methyl-2,3,4,5-tetrahydro-1H-3-
benzazepine
(0.62g, 2.1 mmol) in dichloromethane (10 mL) was treated with N-
chlorosuccinimide (0.284 g, 2.1
mmol) and trifluoromethansulfonic acid (0.639 g, 4.2 mmol). The reaction was
stirred for 16h at
20 C, diluted with water (20 mL) and extracted with dichloromethane (25 mL).
The organics were
10 dried with MgSO4, filtered and concentrated. HPLC purification was done to
provide 0.078 g of a
white solid. 1H NMR (400 MHz, CDC13, mixture of rotamers) 8 7.32-7.25 (m, 1H),
6.97-6.93 (m,
111), 4.27-4.24 (m, 0.6H), 4.19-4.13 (m, 1H), 4.08-4.01 (m, 1H), 3.91-3.86
(0.811, m), 3.74-3.69
(m, 0.811), 3.45-3.37 (in, 1H), 3.31-3.21 (m, 111), 2.96-2.80 (m, 1H), 1.28-
1.22 (m, 311). MS
calculated for C13H12C12F3NO+H: 326, observed: 326.
15 Step 3: Preparation of (S)-8,9-dichloro-l-methyl-2,3,4,5-tetrahydro-1H-3-
benzazepine.
A solution of (S)-N-trifluoroacetyl-8,9-dichloro-l-methyl-2,3,4,5-tetrahydro-
lH-3-
benzazepine (0.270 g, 1.2 mmol) in methanol (10 mL) was treated with 15%
aqueous NaOH (10
mL), and stirred for 3.5 hours at 25 C. The product mixture was concentrated,
extracted 3 times
20 with CH2C12 (25 mL), dried with Na2SO4 and concentrated to give 0.270 g of
a clear oil. 111 NMR
(400 MHz, CDC13) 8 7.40 (d, J=8 Hz, 1 H), 7.16 (d, J=8 Hz, 1 H), 4.17 (m, 1
H), 3.55 (m, 2 H),
3.5-3.3 (m, 2 H), 3.2-3.0 (m, 2 H), 1.43 (d, J=7 Hz, 3 H). MS calculated for
C11H13C12N+H: 230,
observed: 230.
25 Example 3.6: Preparation of (S)-8-chloro-9-fluoro-l-methyl-2,3,4,5-
tetrahydro-1H-3-
benzazepine (Compound 6).
F
CI
NH
Step 1: Preparation of (S)-N-Trifluoroacetyl-8-chloro-9-fluoro-l-methyl-
2,3,4,5-
tetrahydro-1H-3-benzazepine.
30 A solution of (S)-N-trifluoroacetyl-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-
3-benzazepine
(2.5 g, 8.5 mmol) in 1,2-dichloroethane (15 mL) was treated with Selectfluor
(3.9 g, 11 mmol),
trifluoromethanesulfonic acid (8 mL, 90 mmol) and stirred 60 hours at 75 C.
The product mixture
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
51
was poured into water (200 mL), extracted with EtOAc (200 mL), the organic
phase washed with
saturated aqueous NaHCO3 (2 x 100 mL), brine (100 mL), dried with Na2SO4 and
concentrated.
The crude product was purified by flash chromatography (6 % EtOAc in hexane,
silica) resulting in
0.6 g of a white solid. MS calculated for C13H12C1F4NO+H: 310, observed: 310.
Step 2: Preparation of (S)-8-chloro-9-fluoro-l-methyl-2,3,4,5-tetrahydro-lH-3-
benzazepine.
A solution of (S)-N-trifluoroacetyl-8-chloro-9-fluoro-l-methyl-2,3,4,5-
tetrahydro-lH-3-
benzazepine (160 mg, 0.22 mmol) in methanol (3 mL) was treated with 15%
aqueous NaOH (2
mL), and stirred for 3.5 hours at 25 C. The product mixture was concentrated,
extracted 3 times
with CH2C12 (5 mL), dried with Na2SO4 and concentrated to give 93 mg of a
clear oil. 1H NMR
(400 MHz, CDC13) 8 7.06 (dd, J=8, 8 Hz, 1 H), 6.75 (d, J=8 Hz, 1 H), 3.58 (m,
1 H), 3.25-3.15 (m,
3 H), 2.93 (d, J=13 Hz, 1 H) 2.75-2.60 (m, 3H), 1.96 (bs, 1 H), 1.33 (d, J=8
Hz, 3 H). MS
calculated for C11H13C1FN+H: 214, observed: 214.
Example 3.7: Preparation of (R)-8,9-dichloro-l-methyl-2,3,4,5-tetrahydro-1H-3-
benzazepine
(Compound 7).
CI
CI
NH
Step 1: Preparation of 2-(4-chlorophenyl)ethyl-N-2-chloropropionamide
To a 1-liter, 3-necked round bottom flask under argon balloon equipped with
reflux
condenser and addition funnel, were added sequentially 2-(4-chlorophenyl)
ethylamine (30 g, 193
mmol), 400 mL acetonitrile, triethylamine (19.5 g, 193 mmol) and 80 mL
acetonitrile. The clear
colorless solution was stirred and cooled to 0 C. 2-Chloropropionyl chloride
(24.5 g, 193 mmol,
distilled) in 5 mL acetonitrile was slowly added over 20 minutes to evolution
of white gas,
formation of white precipitate, and color change of reaction mixture to slight
yellow. An additional
10 mL of acetonitrile was used to rinse the addition funnel. The mixture was
stirred at 0 C for 30
minutes and then warmed to room temperature and stirred vigorously for an
additional one hour.
The yellow reaction mixture was concentrated on the rotary evaporator to a
solid containing
triethylamine hydrochloride (7636 grams). This material was taken up in 100 mL
ethylacetate and
200 mL water, and stirred vigorously. The layers were separated and the
aqueous layer was
extracted with an additional 100 ml, ethylacetate. The combined organic layers
were washed twice
with 25 mL of saturated brine, dried over magnesium sulfate, filtered, and
concentrated to a light
tan solid (41.6 grams, 88 %). TLC in ethylacetate-hexane, 8:2 showed a major
spot two-thirds of
CA 02529320 2011-08-02
52
the way up the plate and a small spot at the baseline. Baseline spot was
removed as follows: This material
was taken up in 40 mL of ethylacetate and hexane was added until the solution
became cloudy. Cooling to
0 C produced a white crystalline solid (40.2 grams, 85 % yield). The product
is a known compound (Hasan
et al., Indian J. Chem., 1971, 9(9), 1022) with CAS Registry No. 34164-14-2.
LC/MS gave product 2.45
minute; 246.1 M++H+. 1H NMR (CDC13): 6 7.2 (dd, 4H, Ar), 6.7 (br S, 1H, NH),
4.38 (q, 1H, CHCH3), 3.5
(q, 2H, ArCH2CH NH), 2.8 (t, 2H, ArCH2), 1.7 (d, 3H, CH3). 13C NMR (CDC13):
169 (1C, C=O), 136 (1C,
Ar-Cl), 132 (1 C, Ar), 130 (2C, Ar), 128 (2C, Ar), 56 (1 C, CHC1), 40 (1 C,
CHN), 34 (1 C, CHAr), 22 (1 C,
CH3).
Step2: Preparation of 8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepin-2-
one.
2-(4-Chlorophenyl)ethyl-N-2-chloropropionamide (10 g, 40.6 mmol) and aluminum
chloride (16 g,
119.9 mmol) were added to a clean dry 100 mL round bottom flask equipped with
an argon balloon, stirring
apparatus, and heating apparatus. The white solid melted to a tan oil with
bubbling at 91 T. (Note: if
impure starting materials are used, a black tar can result but clean product
can still be isolated). The mixture
was heated and stirred at 150 C for 12 hours. The reaction can be followed by
LC/MS with the starting
material at 2.45 minutes (246.1 M++H), the product at 2.24 minutes (209.6
M++H+) on a 5 minute reaction
time from 5-95% w/ 0.01 % TFA in water/MeCN(50:50). After cooling to room
temperature, the reaction
mixture was quenched with slow addition of 10 mL of MeOH followed by 5 mL of 5
% HCl in water and 5
mL of ethyl acetate. After separation of the resulting layers, the aqueous
layer was extracted a second time
with 10 mL of ethyl acetate. The combined organic layers were dried over
magnesium sulfate, filtered, and
concentrated to a tan solid (6.78 grams, 80 % yield). LC/MS showed one peak,
at 2.2 min and 209.6 MI.
This material was taken up in ethyl acetate, filtered through celiteTM and
Kieselgel 60 (0.5 inch plug on a 60
mL Buchner funnel) and the filtrate was recrystallized from hexane/ethyl
acetate to give final product (4.61
grams, 54 % yield). 1H NMR (CDC13): S 7.3-7.1 (m, 3H, Ar), 5.6 (br s, 1H, NH),
4.23 (q, 1H, CHCH3), 3.8
(m, 1H, ArCH2CH NH), 3.49 (m, 1 H, ArCH2CH NH), 3.48 (m, I H, ArCH CH2NH),
3.05 (m, 1H,
ArCH2CH2NH), 1.6 (d, 3H, CH2). 13C NMR (CDC13): 178 (1C, C=O), 139 (1C, Ar),
135 (1C, Ar), 130, 129
(2C, Ar), 126 (2C, Ar), 42 (IC, C), 40 (1C, CHN), 33 (IC, CHAr), 14 (IC, CH3).
Step 3: Preparation of 8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine.
8-Chloro-l-methyl-2,3,4,5-tetrahydro-]H-3-benzazapin-2-one (150 mg, 0,716
mmol, purified by
HPLC or recrystallization) was added to a 50 mL round bottom flask with 2M
borane-tetrahydrofuran
solution (2 mL, 2.15 mmol). The mixture was stirred 10 hours at room
temperature under an argon balloon.
LC/MS showed the desired product as the major peak with approximately 5 % of
starting material still
present. The reaction mixture was quenched with 5 mL methanol and
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
53
the solvents were removed on the rotary evaporator. This procedure was
repeated with methanol
addition and evaporation. The mixture was evaporated on the rotary evaporator
followed by 2 hours
in vacuo to give the product as a white solid (117 mg, 70 % yield). 1H NMR
(CDC13): S 10.2 (br s,
1H), 9.8 (br s, 1H), 7.14 (dd, 1H, J = 2, 8 Hz), 7.11 (d, 1H, J = 2 Hz), 7.03
(d, 1H, J = 8 Hz), 3.6
(m, 2H), 3.5 (m, 2H), 2.8-3.0 (m, 3 H), 1.5 (d, 3H, J = 7 Hz). LC/MS: 1.41
minute, 196.1 M + H+
and 139 major fragment.
Step 4: Preparation of L-(+)-tartaric acid salt of (R)-8-chloro-l-methyl-
2,3,4,5-
tetrahydro-lH-3-benzazepine.
To a clean, dry 50 mL round bottom flask were added 11.5 g (0.06 mol) of 8-
chloro-l-
methyl-2,3,4,5-tetrahydro-lH-3-benzazepine to 2.23 g (0.015 mol) of L-(+)-
tartaric acid. The
suspension was diluted with 56 g of tert-butanol and 6.5 mL of H2O. The
mixture was heated to
reflux (75-78 C) and stirred for 10 min to obtain a colorless solution. The
solution was slowly
cooled down to room temperature (during lh) and stirred for 3h at room
temperature. The
suspension was filtered and the residue was washed twice with acetone (10 mL).
The product was
dried under reduced pressure (50 mbar) at 60 C to yield 6.3 g of the tartrate
salt (ee = 80). This
tartrate salt was added to 56 g of tert-butanol and 6.5 mL of H2O. The
resulting suspension was
heated to reflux and 1 to 2g of H2O was added to obtain a colorless solution.
The solution was
slowly cooled down to room temperature (over the course of lh) and stirred for
3h at room
temperature. The suspension was filtered and the residue was washed twice with
acetone (10 mL).
The product was dried under reduced pressure (50 mbar) at 60 C to produce 4.9
g (48 % yield) of
product (ee >98.9). 1
Step 5: Conversion of Salt to Free Amine - (R)-8-chloro-l-methyl-2,3,4,5-
tetrahydro-
1H-3-benzazepine.
The L-tartaric acid salt of 8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-
benzazepine (300 mg,
0.87 mmol) was added to a 25 mL round bottom flask with 50% sodium hydroxide
solution (114
L, 2.17 mmol) with an added 2 mL of water. The mixture was stirred 3 minutes
at room
temperature. The solution was extracted with methylene chloride (5 mL) twice.
The combined
organic extracts were washed with water (5 nL) and evaporated to dryness on
the pump to afford
free amine (220 mg crude weight). LC/MS 196 (M+H).
Step 6: Preparation of (R)-N-Trifluoroacetyl-8-chloro-l-methyl-2,3,4,5-
tetrahydro-1H-3-
benzazepine.
A solution of (R)-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine
hydrochloride
salt (1.0 g, 4.3 lmmol) in dichloromethane (50 niL) at 0 C was treated with
pyridine (1.0 mL) and
trifluoroacetic anhydride (1.35 g, 6.46 mmole). This was warmed to 20 C,
stirred for 3h and
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
54
diluted with 1M HCl (25 mL). This was extracted with dichloromethane (2 x 50
mL) and the
organics dried with MgSO4, filtered and concentrated to give 1.17 g as an off-
white solid. 1H NMR
(400 MHz, CDC13, mixture of rotamers) 8 7.27 (m, 1H), 6.96 (m, 1H), 4.26 (bm,
0.6H), 4.19-4.03
(m, 1.7H), 3.92-3.87 (m, 0.8H), 3.75-3.69 (m, 0.8H), 3.47-3.22 (m, 2H), 2.91
(m, 1H), 1.28-1.25
(m, 3H). MS calculated for C13H13C1F3NO+H: 292, observed: 292.
Step 7: (R)-8,9-dichloro-l-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
Compound 7 was prepared from (R)-N-trifluoroacetyl-8-chloro-l-methyl-2,3,4,5-
tetrahydro-1H-3-benzazepine utilizing a similar two step procedure as
described herein for the
preparation of Compound 5. 1H NMR (400 MHz, CDC13) 6 7:40 (d, J=8 Hz, 1 H),
7.16 (d, J=8 Hz,
1 H), 4.17 (m, 1 H), 3.55 (m, 2 H), 3.5-3.3 (m, 2 H), 3.2-3.0 (m, 2 H), 1.43
(d, J=7 Hz, 3 H). MS
calculated for C11H13C12N+H: 230, observed: 230.
Example 3.8: Preparation of (S)-9-bromo-8-chloro-l-methyl-2,3,4,5-tetrahydro-
1H-3-
benzazepine (Compound 8).
Br
CI
NH
Step 1: - Preparation of (S)-N-Trifluoroacetyl-9-bromo-8-chloro-l-methyl-
2,3,4,5-
tetrahydro-1 H-3-b enzazepine.
A solution of (S)-N-Trifluoroacetyl-8-chloro-l-methyl-2,3,4,5-tetrahydro-1H-3-
benzazepine
(0.875g, 3.0 mmol) in dichloroethane (7 mL) was treated with N-
bromosuccinimide (0.284 g, 2.1
mmol) and trifluoromethansulfonic acid (0.639 g, 4.2 mmol). The reaction was
stirred for 16h at
75 C, diluted with ethyl acetate (20 mL) and extracted with water (2x10 mL).
The organics were
dried with MgSO4, filtered and concentrated. Flash chromatography (5 % EtOAc
in hexanes, silica)
resulted in 0.13 g of a clear oil. MS calculated for C13H12BrC1F3NO+H: 370,
observed: 370.
Step 2: Preparation of (S)-9-bromo-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-
benzazepine.
Compound 8 was prepared from (S)-N-trifluoroacetyl-9-bromo-8-chloro-l-methyl-
2,3,4,5-
tetrahydro- 1H-3-benzazepine utilizing a similar procedure as described herein
for the preparation of
Compound 5. (S)-9-bromo-8-chloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine
was obtained
from (S)-N-trifluoroacetyl-9-bromo-8-chloro-l -methyl-2,3,4,5-tetrahydro-lH-3-
benzazepine. 1H
NMR (400 MHz, CDC13) 8 7.17 (d, J = 8 Hz, 1H), 6.92 (d, J = 8 Hz, 1H), 3.92-
3.87 (m, 1H), 3.29-
3.20 (m, 2H), 3.11 (dd, J = 14, 5 Hz, 1H), 2.99 (dd, J = 14, 2 Hz, 1H), 2.74-
2.65 (in, 2H), 1.32 (d,
J = 7 Hz, 3H). MS calculated for C11H13BrC1N+H: 274, observed: 274.
CA 02529320 2005-12-12
WO 2005/003096 PCT/US2004/019670
Example 3.9: Preparation of (R)-N-methyl-8,9-dichloro-l-methyl-2,3,4,5-
tetrahydro-1H-3-
benzazepine (Compound 9).
CI
CI
I N-
5 A solution of (R)-8,9-dichloro-l-methyl-2,3,4,5-tetrahydro-lH-3-benzazepine
(0.05g, 0.20
mmol) in dichloroethane (3mL) was treated with sodium triacetoxyborohydride
(0.073g, 0.35
mmol) and formaldehyde (0.0 17 mL, 37% solution in water). This was stirred at
20 C for 2h. The
reaction was diluted with 15% NaOH and extracted with ethyl acetate (2x10 mL).
The organics
were dried with MgSO4, filtered and concentrated to give 0.042 g as an oil. 1H
NMR (400 MHz,
10 CDC13) 8 7.19 (d, J = 8 Hz, 1H), 6.89 (d, J = 8 Hz, 1H), 3.91-3.88 (m, 1H),
3.28 (ddd, J = 15, 12, 2
Hz, 1H), 2.99-2.88 (m, 2H), 2.68 (ddd, J = 15, 5, 1 Hz, 1H), 2.36-2.32 (m,
4H), 2.13 (t, J = 11 Hz,
1H), 1.27 (d, J = 7 Hz, 3H). MS calculated for C12H15C12N+H: 243, observed:
243.
Example 3.10: Preparation of (S)-N-methyl-8,9-dichloro-l-methyl-2,3,4,5-
tetrahydro-1H-3-
15 benzazepine (Compound 10).
CI
CI
Step 1: Preparation of (S)-N-methyl-8,9-dichloro-l-methyl-2,3,4,5-tetrahydro-
lH-3-
benzazepine.
Compound 10 was prepared from (S)-8,9-dichloro- 1 -methyl-2,3,4,5 -tetrahydro-
1H-3 -
20 benzazepine utilizing a similar procedure as described herein for the
preparation of Compound 9.
1H NMR (400 MHz, CDC13) 8 7.19 (d, J = 8 Hz, 1H), 6.89 (d, J = 8 Hz, 1H), 3.91-
3.88 (m, 1H),
3.28 (ddd, J = 15, 12, 2 Hz, 1H), 2.99-2.88 (m, 2H), 2.68 (ddd, J = 15, 5, 1
Hz, 1H), 2.36-2.32 (m,
4H), 2.13 (t, J = 11 Hz, 1H), 1.27 (d, J = 7 Hz, 3H). MS calculated for
C12H15C12N+H: 243,
observed: 243.
Example 3.11: Preparation of (S)-N-methyl-9-bromo-8-chloro-l-methyl-2,3,4,5-
tetrahydro-
1H-3-benzazepine (Compound 11).
Br
CI
N-
CA 02529320 2011-08-02
56
Compound 11 was prepared from (S)-9-bromo-8-chloro-l-methyl-2,3,4,5-tetrahydro-
1H--3-
benzazepine utilizing a similar procedure as described herein for the
preparation of Compound 9. 'H
NMR (400 MHz, CDC13) S 7.18 (d, J = 8 Hz, 1H), 6.92 (d, J = 8 Hz, 1H), 3.94-
3.88 (m, 1H), 3.29 (ddd,
J = 15, 12, 2 Hz, 1H), 2.98-2.93 (m, 1H), 2.90 (ddd, J = 15, 6,1 Hz, 1H), 2.36-
2.32 (m, 4H) 2.13 (t, J =
11 Hz, 1H), 1.33 (d, J = 7 Hz, 3H). MS calculated for C12H15C12N+H: 288,
observed: 288.
Example 4 Separation of enantiomers for selected compounds of the invention
Compounds of the present invention can be separated into their respective
enantiomers using a
Varian ProStarTM HPLC system with a 20 mm x 250 mm ChiralcelTM OD chiral
column, eluting with 0.2
% diethylamine in various concentrations of isopropanol (IPA) in hexanes, for
example, 5% IPA in
hexanes, 1 % IPA in hexanes and like concentrations.
Those skilled in the art will appreciate that numerous changes and
modifications may be made to
the preferred embodiments of the invention and that such changes and
modifications may be made
without departing from the spirit of the invention. It is therefore intended
that the appended claims cover
all such equivalent variations as fall within the true spirit and scope of the
invention.
